

WO2004092208

Publication Title:

SARS-RELATED PROTEINS

Abstract:

< 13a2 !-- like parent-table TOP-BOTTOM rows and LEFT-RIGHT columns for
tableborder --> Abstract of WO2004092208

Novel proteins isolated from a patient with SARS are described. Data supplied
from the esp@cenet database - Worldwide

Courtesy of <http://v3.espacenet.com>

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 October 2004 (28.10.2004)

PCT

(10) International Publication Number
WO 2004/092208 A2

(51) International Patent Classification⁷: **C07K 14/165**

(21) International Application Number:
PCT/CA2004/000558

(22) International Filing Date: 14 April 2004 (14.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/462,688 15 April 2003 (15.04.2003) US
60/472,416 22 May 2003 (22.05.2003) US

(71) Applicants (for all designated States except US): **HER MAJESTY THE QUEEN IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF HEALTH** [CA/CA]; 1015 rue Arlington Piece T2420, Winnipeg, Manitoba R3E 3P6 (CA). **UNIVERSITY OF MANITOBA** [CA/CA]; 631 Drake Centre, Winnipeg, Manitoba R3T 5V4 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **JONES, Steven** [CA/CA]; 1015, rue Arlington pieceT2420, Winnipeg, Manitoba R3E 3P6 (CA). **FELDMANN, Heinz** [CA/CA]; 1015, rue Arlington pieceT2420, Winnipeg, Manitoba R3E 3P6 (CA). **BASTIEN, Nathalie** [CA/CA]; 1015, rue Arlington pieceT2420, Winnipeg, Manitoba R3E 3P6 (CA). **LI, Yan** [CA/CA]; 1015, rue Arlington pieceT2420, Winnipeg, Manitoba R3E 3P6 (CA). **PLUMMER, Frank** [CA/CA]; 1015, rue Arlington pieceT2420, Winnipeg,

Manitoba R3E 3P6 (CA). **ENS, Werner** [CA/CA]; 631 Drake Centre, Winnipeg, Manitoba R3T 5V4 (CA). **STANDING, Kenneth** [CA/CA]; 631 Drake Centre, Winnipeg, Manitoba R3T 5V4 (CA). **KROKHINE, Oleg** [CA/CA]; 631 Drake Centre, Winnipeg, Manitoba R3T 5V4 (CA). **PERREAULT, Helen** [CA/CA]; 631 Drake Centre, Winnipeg, Manitoba R3T 5V4 (CA). **TYLER, Shaun** [CA/CA]; 1015 rue Arlington Piece T2420, Winnipeg, Manitoba R3E 3P6 (CA).

(74) Agent: **ADE & COMPANY**; 1700-360 Main Street, Winnipeg, Manitoba R3C 3Z3 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: SARS-RELATED PROTEINS

47 kDa protein sequence, noon Apr 15, 2003

MW 45936.94 average, 421 aa, 93 % sequence coverage (confirmed residues indicated in red). @S indicates acetylation of the N-terminal serine residue (yielding a mass change +42.011 Da)

1 @SDNGPQSNQR SAPRITFGGP TDSTDNNQNG GRNGARPKQR RPQGLPNNTA SWFTALTQHG
61 KEELRFPRGQ GVPINTNSGP DDQIGYYRRA TRRVRGGDGK MKELSPRWYF YYLGTGPEAS
121 LPYGANKEGI VWVATEGALN TPKDHIGTRN PNNNAATVLQ LPQGTTLPKG FYAEGSRGGS
181 QASSRSSRS RGNSRNPSTPG SSRGNSPARN ASGGGETALA LLLLDRLNQL ESKVSGKGQQ
241 QQGQTVTKKS AAEASKKPRQ KRTATKQYNV TQAFGRRGPE QTQGNFGDQD LIRQGTDYKH
301 WPQIAQFAPS ASAFFGMSRI GMEVTPSGTW LTYHGAIKLD DKDPQFKDNV ILLNKHIDAY
361 KTFPPTEPKK DKKKKTDEAQ PLPQRQKKQP TVTLLPAADM DDFSRLQNS MSGASADSTQ
421 A

(57) Abstract: Novel proteins isolated from a patient with SARS are described.

WO 2004/092208 A2



Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

SARS-RELATED PROTEINS

PRIOR APPLICATION INFORMATION

This application claims priority on USSN 60/462,688, filed April 15, 2003 and USSN 60/472,416, filed May 22, 2003.

FIELD OF INVENTION

The present invention relates to novel proteins isolated from a patient with Severe Acute Respiratory Syndrome (SARS). The invention also relates to the uses of said proteins in the therapy and diagnosis of SARS.

BACKGROUND OF THE INVENTION

The recent clinical identification of a novel type of atypical pneumonia without a clearly defined etiology, together with epidemiological evidence of high transmissibility, have provoked the World Health Organization to issue a rare travel advisory. The new entity has been called severe acute respiratory syndrome (SARS); it apparently began in Guangdong province in China in November of 2002, and it has since spread to Hong Kong, Singapore, Vietnam, Canada, the USA, Taiwan and several European countries. The outbreak in Canada began in late February 2003 in a traveler returning from Hong Kong, whose exposure was to the index case in the Hong Kong epidemic (a physician who had cared for SARS cases in Guangdong province in the People's Republic of China). The Canadian index case died nine days after the disease onset and a 43-year-old male relative became ill 2 days after exposure and died of the adult respiratory distress syndrome 15 days after the illness began (1). Subsequently Canada has faced the largest SARS outbreak outside of Asia with at least 303 probable and suspected cases and 24 deaths, mostly in the Toronto area (2).

Samples from patients with suspect or probable SARS in Canada have been referred to the National Microbiology Laboratory (NML), Health Canada, for laboratory diagnostics. This laboratory, part of the Canadian Science Centre for Human and Animal Health, is Canada's national reference centre for infectious diseases, and houses the only Class 4 containment facilities in the country. NML has played an active role in an

intensive international collaborative effort among eleven laboratories around the world that suggested a distinct coronavirus may be etiologically involved. In particular, the laboratory prepared the nucleotide samples for the first successful effort to determine the genome sequence for the coronavirus (3), a
5 result soon confirmed by several other laboratories; see, for example, ref. (4).

Nevertheless, the genome sequence merely provides a template for the construction of the viral proteins. Thus an alternative strategy is to examine the proteins themselves, and mass spectrometry has proved to be an efficient tool for this purpose (5).

10 **SUMMARY OF THE INVENTION**

The present inventors have isolated and sequenced novel proteins from a biological sample from a patient with Severe Acute Respiratory Syndrome (SARS).

In accordance with one embodiment of the invention, there is
15 provided an isolated SARS-related protein from a SARS patient. In a specific embodiment, the SARS-related protein has the amino acid sequence shown in Figure 1 (SEQ ID No. 1) or 2 (SEQ ID No. 2).

This invention is also directed to the use of the SARS-related proteins or a fragment thereof for the preparation of a vaccine to treat SARS.

20 This invention is directed to the use of the SARS-related proteins or a fragment thereof for the preparation of antibodies, including polyclonal antibodies, monoclonal antibodies or functional fragment thereof. This invention also relates to the antibodies so produced.

This invention is also directed to vaccines prepared from said
25 antibodies or SARS-related proteins or a fragment thereof, for the treatment or prevention of virally mediated, preferably, coronavirus mediated, diseases.

This invention is directed to the use of said antibodies or SARS-related proteins, or a fragment thereof, as a diagnostic to screen for the presence of SARS.

30 This invention is directed to the use of the SARS-related protein or a fragment thereof as a drug development tool.

The invention is yet further directed to a method of treating a condition associated with a virus, preferably a coronavirus, comprising of administering to a cell or animal in need thereof, an effective amount of agent that modulates the expression and/or activity of a SARS-related protein of the
5 invention. In a preferred embodiment, the condition to be treated is SARS.

Other features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of
10 illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from the detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

These and other features of the invention will become more
15 apparent from the following description in which reference is made to the appended drawings wherein:

Figure 1 shows the amino acid sequence of the 47 kDa SARS-related protein (SEQ ID No. 1).

Figure 2 shows the amino acid sequence of the 139 kDa SARS-
20 related protein (SEQ ID No. 2).

Figure 3 shows the analysis of proteins from a new corona virus associated with SARS. A) The viral particles pelleted from the supernatant of vero E6 cells exposed to samples derived from patients with SARS (lanes 1) or from mock infected cells processed in a similar fashion (lanes 2) were
25 separated by SDS PAGE and analysed by western blot with convalescent sera from SARS patients (Tor 2, Tor 3, Tor 4, and BC 1) or a control serum from a non infected donor (NML). The sera from the patients but not the control reacted with a 44-48 kDa species present in the supernatants from the infected but not the mock treated cultures (indicated by arrow head). B) A
30 virus sample similar to that described in A) was fractionated on a sucrose gradient. The fraction containing immunoreactive material was separated on a 4-12% bis acrylamide gradient gel and stained with colloidal Coomassie

blue. A prominent band with an apparent molecular weight of 44-48 kDa was observed along with much less intensive at ~180 kDa (indicated by arrow head). These bands were excised and used for the mass spectrometric studies described in the text.

5 Figure 4. A) Single-MS spectrum of the peptide mixture obtained from tryptic digestion of the 47 kDa protein prior to HPLC fractionation. B) A small section of the MALDI mass spectrum of a mixture of tryptic peptides from the 47 kDa protein. C) Same section of the spectrum obtained from fraction 23 of the HPLC separation of the mixture. The peak
10 labels indicate the residue numbers corresponding to the intact protein; in one case loss of 64 Da is indicated. The intense peak corresponding to T277-293 in the mixture is absent in fraction 23 (it elutes in fraction 21), but several weaker peaks that are present, like T389-405, are significantly enhanced by the HPLC. The improvement helps to identify them, and is essential for high
15 mass accuracy and for subsequent MS/MS analysis. Measured and predicted masses for all the tryptic peptides can be found in Table 2; Dm is less than 10 mDa in nearly every case.

 Figure 5. MS/MS spectrum of tryptic fragment of m/z 2297 after digestion in 50/50 mixture of normal and O-18 labeled water. The complete
20 spectrum is shown in A, with the amino acid sequence indicated between the y-series fragments. An example of a b-series fragment is shown in B, and of a y-series fragment in C. The signature isotopic pattern of fragments containing the C-terminus is visible in C. The measured and predicted masses for all identified peaks are shown in Table 1.

25 Figure 6 shows the sequence alignment of the coronavirus nucleocapsid protein.

 Figure 7. Direct MS (A, B) and MS/MS (C) detection of glycosylated tryptic peptides of the 139 kDa spike protein. A) MS spectrum of HPLC fraction #21 of tryptic digest of the 180 kDa band. Labeled peaks are
30 the monoisotopic [M+H]⁺ ions of glycosylated forms of T111-126 (see Table 3). B) MS spectrum of HPLC fraction #25 showing forms of glycosylated

T222-232. C) MS/MS spectra of the 3122.373 Da peak from B. D) Suggested N-glycan structures.

Figure 8. MS/MS spectrum of the tryptic fragment of m/z 1144 representing the N-terminal end of the 47 kDa protein. The amino acid sequence is indicated between the y -series fragments. The difference between measured and calculated masses of N-terminal Ser residue (42.015 Da) correspond to N-terminal acetylation, a post-translational modification ($Dm=42.011$ Da).

Figure 9. Comparison of (A) tryptic and (B) Lys-C digestion for the same region of the 47 kDa protein. Two additional residues (QK) are present in the Lys-C digest because it does not cleave at arginine. Both digestions were performed in the presence of a 50/50 mixture of normal and O-18 water. The signature isotopic pattern shown in the inset (A) is a characteristic of all digestion fragments except the one that contains the C-terminal of the protein. The two peaks at nominal m/z 1410 in A and B correspond to peptides containing the same residues except for a K/Q difference. The expected mass difference is 36 mDa; our measurement shows a 35 mDa difference.

Figure 10. Mass spectrum of fraction # 12 of the 46 kDa protein tryptic digest. The digestion took place in the presence of a 50/50 mixture of normal and O-18 water. The peak shown does not exhibit the characteristic isotopic pattern for O-18 C-terminal labeling after tryptic cleavage, suggesting it is the C-terminal peptide. This was confirmed by subsequent MS/MS analysis, which reveals a sequence consistent with the C-terminus of the predicted 46 kDa protein: QLQNSM*SGASADSTQA (M^* - oxidized methionine residue).

Figure 11. A) The deduced sequence of the 47-kDa SARS nucleocapsid protein. The underlined sequences were not identified by MS. The 5 SRXX motifs are indicated by red letters. B) Phylogenetic tree analysis of different coronavirus N protein sequences.

Figure 12. MS and MS/MS identification of deglycosylated peptides from the 139 kDa spike protein. A) MS spectrum of HPLC fraction

#26 showing deglycosylated T222-232. B) MS/MS spectrum of deglycosylated LPLGIDITNFR at 1258.715 Da (see Table 4).

DESCRIPTION OF PREFERRED EMBODIMENT

The inventors have determined that sera from a SARS patient
5 contained a dominant viral antigen that was identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOFMS) as a ~47 kDa protein species. This was found to be a novel nucleocapsid protein. A second viral protein corresponding to the predicted ~139 kDa spike glycoprotein has also been examined by MALDI-TOFMS (42% coverage)
10 (Krokhin et al., 2003, *Mol. Cell. Proteomics* 2: 346-356, incorporated herein by reference). After pNGase F digestion, nine glycosylation sites in this protein were confirmed. The sugars attached to four of the sites were also identified. These results suggest that the nucleocapsid protein and the spike glycoprotein are major immunogens that may be useful for early diagnostics,
15 or of prophylactic value in combating SARS.

I. Novel Proteins of the Invention

The invention relates to isolated proteins that have been isolated and sequenced from a patient with SARS. For ease of referral, the proteins of the invention are generally referred to SARS-related proteins. The
20 term "SARS-related proteins" as used herein includes the proteins shown in Figures 1 (SEQ ID No. 1) and 2 (SEQ ID No. 2) as well as all homologs, analogs, fragments or derivatives of the SARS-related proteins.

In one embodiment, the isolated SARS-related protein has a molecular weight of approximately 47 kDa and an amino acid sequence as
25 shown in Figure 1. Sequence analysis reveals that this protein shares 32% homology with coronavirus nucleocapsid proteins (Figure 6) although there are significant differences in the sequences. Accordingly, the present invention provides an isolated nucleocapsid protein comprising a sequence that is at least 35% homologous, preferably at least 40% homologous with the
30 sequence shown in Figure 1. The inventors have further characterized the nucleocapsid protein of the invention using mass spectroscopy as described in Example 1 and the Figures and Tables.

In another embodiment, the isolated SARS-related protein has a molecular weight of 139 kDa and an amino acid sequence shown in Figure 2. Sequence analysis reveals that this protein shares homology to coronavirus spike glycoproteins and structural proteins. The inventors have further
5 characterized the spike glycoprotein of the invention using mass spectroscopy as described in Example 1 and the Figures and Tables.

Within the context of the present invention, a SARS-related protein of the invention may include various structural forms of the primary protein which retain biological activity. For example, a SARS-related protein
10 of the invention may be in the form of acidic or basic salts or in neutral form. In addition, individual amino acid residues may be modified by oxidation or reduction.

In addition to the full length amino acid sequence, the SARS-related proteins of the present invention may also include truncations of the protein, and analogs, and homologs of the protein and truncations thereof as
15 described herein. Truncated SARS-related proteins or fragments may comprise peptides of at least 5, preferably 10 and more preferably 15 amino acid residues of the sequence shown in Figure 1 or 2. In other embodiments, truncated SARS-related proteins or fragments may comprise peptides of at
20 least 5, at least 6, at least 7, at least 8, preferably 10 or more preferably 15 consecutive or contiguous amino acid residues of the sequence shown in Figure 1 or 2.

The invention further provides polypeptides comprising at least one functional domain or at least one antigenic determinant of a SARS-
25 related protein.

Analogous of the protein of the invention and/or truncations thereof as described herein, may include, but are not limited to an amino acid sequence containing one or more amino acid substitutions, insertions, and/or deletions. Amino acid substitutions may be of a conserved or non-conserved
30 nature. Conserved amino acid substitutions involve replacing one or more amino acids of the proteins of the invention with amino acids of similar charge, size, and/or hydrophobicity characteristics. When only conserved

substitutions are made the resulting analog should be functionally equivalent. Non-conserved substitutions involve replacing one or more amino acids of the amino acid sequence with one or more amino acids which possess dissimilar charge, size, and/or hydrophobicity characteristics.

5 One or more amino acid insertions may be introduced into the amino acid sequences of the invention. Amino acid insertions may consist of single amino acid residues or sequential amino acids ranging from 2 to 15 amino acids in length. For example, amino acid insertions may be used to destroy target sequences so that the protein is no longer active. This
10 procedure may be used *in vivo* to inhibit the activity of a protein of the invention.

 Deletions may consist of the removal of one or more amino acids, or discrete portions from the amino acid sequence of the SARS-related protein. The deleted amino acids may or may not be contiguous. The lower
15 limit length of the resulting analog with a deletion mutation is about 10 amino acids, preferably 100 amino acids.

 According to another embodiment of the invention, there are provided nucleic acid molecules deduced from the amino acid sequences or fragments thereof of the SARS-related proteins. As will be appreciated by one
20 of skill in the art, the nucleic acid molecules may be inserted into any expression vector known in the art for expression in a suitable host. Furthermore, it is of note that the codons selected for the nucleic acid molecules may be selected in accordance with codon usage tables for the intended expression system host, thereby maximizing expression.

25 Analogues of a protein of the invention may be prepared by introducing mutations in the nucleotide sequence encoding the protein. Mutations in nucleotide sequences constructed for expression of analogs of a protein of the invention must preserve the reading frame of the coding sequences. Furthermore, the mutations will preferably not create
30 complementary regions that could hybridize to produce secondary mRNA structures, such as loops or hairpins, which could adversely affect translation of the receptor mRNA.

Mutations may be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling ligation to fragments of the native sequence. Following ligation, the resulting reconstructed sequence encodes an analog having the desired amino acid insertion, substitution, or deletion.

Alternatively, oligonucleotide-directed site specific mutagenesis procedures may be employed to provide an altered gene having particular codons altered according to the substitution, deletion, or insertion required. Deletion or truncation of a protein of the invention may also be constructed by utilizing convenient restriction endonuclease sites adjacent to the desired deletion. Subsequent to restriction, overhangs may be filled in, and the DNA religated. Exemplary methods of making the alterations set forth above are disclosed by Sambrook et al (Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, 1989).

The SARS-related proteins of the invention also include homologs of the amino acid sequence of the SARS-related protein and/or truncations thereof as described herein. Such homologs are proteins whose amino acid sequences are comprised of amino acid sequences that hybridize under stringent hybridization conditions, for example, such homologs will cross-react with antibodies raised against the SARS-related proteins or fragments thereof. Homologs of a SARS-related protein of the invention will have the same regions which are characteristic of the protein.

A homologous protein includes a protein with an amino acid sequence having at least 60%, preferably at least 70%, more preferably 80-95% identity with the amino acid sequence of the SARS-related protein.

The invention also contemplates isoforms of the proteins of the invention. An isoform contains the same number and kinds of amino acids as a protein of the invention, but the isoform has a different molecular structure. The isoforms contemplated by the present invention are those having the same properties as a protein of the invention as described herein.

The present invention also includes a protein of the invention conjugated with a selected protein, or a selectable marker protein to produce

fusion proteins. For example, the SARS cDNA sequence, for example, as deduced from the amino acid sequence of one of the SARS-related proteins, as discussed above is inserted into a vector that contains a nucleotide sequence encoding another peptide (e.g. GST-glutathione succinyl
5 transferase). The fusion protein is expressed and recovered from prokaryotic (e.g. bacterial or baculovirus) or eukaryotic cells. The fusion protein can then be purified by affinity chromatography based upon the fusion vector sequence and the SARS-related protein obtained by enzymatic cleavage of the fusion protein.

10 The proteins of the invention (including truncations, analogs, etc.) may be prepared using recombinant DNA methods. Accordingly, nucleic acid molecules of the present invention having a sequence which encodes a protein of the invention may be incorporated according to procedures known in the art into an appropriate expression vector which ensures good
15 expression of the protein. Possible expression vectors include but are not limited to cosmids, plasmids, or modified viruses (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), so long as the vector is compatible with the host cell used. The expression "vectors suitable for transformation of a host cell", means that the expression vectors contain a
20 nucleic acid molecule of the invention and regulatory sequences, selected on the basis of the host cells to be used for expression, which are operatively linked to the nucleic acid molecule. "Operatively linked" is intended to mean that the nucleic acid is linked to regulatory sequences in a manner which allows expression of the nucleic acid.

25 The invention therefore contemplates a recombinant expression vector of the invention containing a nucleic acid molecule of the invention, or a fragment thereof, and the necessary regulatory sequences for the transcription and translation of the inserted protein-sequence. Suitable regulatory sequences may be derived from a variety of sources, including
30 bacterial, fungal, or viral genes (For example, see the regulatory sequences described in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990). Selection of

appropriate regulatory sequences is dependent on the host cell chosen, and may be readily accomplished by one of ordinary skill in the art. Examples of such regulatory sequences include: a transcriptional promoter and enhancer or RNA polymerase binding sequence, a ribosomal binding sequence, 5 including a translation initiation signal. Additionally, depending on the host cell chosen and the vector employed, other sequences, such as an origin of replication, additional DNA restriction sites, enhancers, and sequences conferring inducibility of transcription may be incorporated into the expression vector. It will also be appreciated that the necessary regulatory sequences 10 may be supplied by the native protein and/or its flanking regions.

The invention further provides a recombinant expression vector comprising a DNA nucleic acid molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for 15 expression, by transcription of the DNA molecule, of an RNA molecule which is antisense to a nucleotide sequence of the invention. Regulatory sequences operatively linked to the antisense nucleic acid can be chosen which direct the continuous expression of the antisense RNA molecule.

The recombinant expression vectors of the invention may also 20 contain a selectable marker gene which facilitates the selection of host cells transformed or transfected with a recombinant molecule of the invention. Examples of selectable marker genes are genes encoding a protein such as G418 and hygromycin which confer resistance to certain drugs, β -galactosidase, chloramphenicol acetyltransferase, or firefly luciferase. 25 Transcription of the selectable marker gene is monitored by changes in the concentration of the selectable marker protein such as β -galactosidase, chloramphenicol acetyltransferase, or firefly luciferase. If the selectable marker gene encodes a protein conferring antibiotic resistance such as neomycin resistance transformant cells can be selected with G418. Cells that 30 have incorporated the selectable marker gene will survive, while the other cells die. This makes it possible to visualize and assay for expression of recombinant expression vectors of the invention and in particular to determine

the effect of a mutation on expression and phenotype. It will be appreciated that selectable markers can be introduced on a separate vector from the nucleic acid of interest.

The recombinant expression vectors may also contain genes
5 which encode a fusion moiety which provides increased expression of the recombinant protein; increased solubility of the recombinant protein; and aid in the purification of a target recombinant protein by acting as a ligand in affinity purification. For example, a proteolytic cleavage site may be added to the target recombinant protein to allow separation of the recombinant protein
10 from the fusion moiety subsequent to purification of the fusion protein.

Recombinant expression vectors can be introduced into host cells to produce a transformed host cell. Accordingly, the invention includes a host cell comprising a recombinant expression vector of the invention. The term "transformed host cell" is intended to include prokaryotic and eukaryotic
15 cells which have been transformed or transfected with a recombinant expression vector of the invention. The terms "transformed with", "transfected with", "transformation" and "transfection" are intended to encompass introduction of nucleic acid (e.g. a vector) into a cell by one of many possible techniques known in the art. Prokaryotic cells can be
20 transformed with nucleic acid by, for example, electroporation or calcium-chloride mediated transformation. Nucleic acid can be introduced into mammalian cells via conventional techniques such as calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofectin, electroporation or microinjection. Suitable methods for
25 transforming and transfecting host cells can be found in Sambrook et al. (Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press (1989)), and other such laboratory textbooks.

Suitable host cells include a wide variety of prokaryotic and eukaryotic host cells. For example, the SARS-related proteins of the
30 invention may be expressed in bacterial cells such as *E. coli*, *Pseudomonas*, *Bacillus subtilis*, insect cells (using baculovirus), yeast cells or mammalian cells. Other suitable host cells can be found in Goeddel, Gene Expression

Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1991).

SARS-related proteins may also be isolated from a coronavirus or from a sample from a patient with SARS. The protein may be purified by
5 conventional purification methods known to those in the art, such as chromatography methods, high performance liquid chromatography methods or precipitation.

For example, an anti-SARS-related protein antibody (as described below) may be used to isolate a SARS-related protein, which is
10 then purified by standard methods.

The proteins of the invention may also be prepared by chemical synthesis using techniques well known in the chemistry of proteins such as solid phase synthesis (Merrifield, 1964, J. Am. Chem. Assoc. 85:2149-2154) or synthesis in homogenous solution (Houbenweyl, 1987, Methods of Organic
15 Chemistry, ed. E. Wansch, Vol. 15 I and II, Thieme, Stuttgart).

II. Uses

The present invention includes all uses of the SARS-related proteins of the invention including, but not limited to, the preparation of antibodies, the isolation of substances that modulate SARS-related protein
20 expression and/or activity as well as the use of the proteins and modulators thereof in diagnostic, biomedical, therapeutic and vaccine applications. Some of the uses are further described below.

(a) Antibodies

The isolation of a SARS-related protein enables the preparation
25 of antibodies specific for the virus, likely coronavirus, that is causative of SARS. Accordingly, the present invention provides an antibody that binds to a SARS-related protein. Antibodies can be prepared which bind a distinct epitope in an unconserved region of the SARS-related protein. An unconserved region of the SARS-related protein is one that does not have
30 substantial sequence homology to other proteins, for example, other related viral proteins which have at least one homologous region to a region of said SARS-related protein.

Antibodies to the SARS-related protein may also be prepared using techniques known in the art. For example, by using a peptide of the SARS-related protein, polyclonal antisera or monoclonal antibodies can be made using standard methods. A mammal, (e.g., a mouse, hamster, or
5 rabbit) can be immunized with an immunogenic form of the peptide which elicits an antibody response in the mammal. Techniques for conferring immunogenicity on a peptide include conjugation to carriers or other techniques well known in the art. For example, the protein or peptide can be administered in the presence of adjuvant. The progress of immunization can
10 be monitored by detection of antibody titers in plasma or serum. Standard ELISA or other immunoassay procedures can be used with the immunogen as antigen to assess the levels of antibodies. Following immunization, antisera can be obtained and, if desired, polyclonal antibodies isolated from the sera.

15 To produce monoclonal antibodies, antibody producing cells (lymphocytes) can be harvested from an immunized animal and fused with myeloma cells by standard somatic cell fusion procedures thus immortalizing these cells and yielding hybridoma cells. Such techniques are well known in the art, (e.g., the hybridoma technique originally developed by Kohler and
20 Milstein (Nature 256, 495-497 (1975)) as well as other techniques such as the human B-cell hybridoma technique (Kozbor et al., Immunol. Today 4, 72 (1983)), the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al. Monoclonal Antibodies in Cancer Therapy (1985) Allen R. Bliss, Inc., pages 77-96), and screening of combinatorial antibody
25 libraries (Huse et al., Science 246, 1275 (1989)). Hybridoma cells can be screened immunochemically for production of antibodies specifically reactive with the peptide and the monoclonal antibodies can be isolated. Therefore, the invention also contemplates hybridoma cells secreting monoclonal antibodies with specificity for a SARS-related protein as described herein.

30 The term "antibody" as used herein is intended to include fragments thereof which also specifically react with a SARS-related protein or fragments thereof. Antibodies can be fragmented using conventional

techniques and the fragments screened for utility in the same manner as described above. For example, F(ab')₂ fragments can be generated by treating antibody with pepsin. The resulting F(ab')₂ fragment can be treated to reduce disulfide bridges to produce Fab' fragments.

5 Chimeric antibody derivatives, i.e., antibody molecules that combine a non-human animal variable region and a human constant region are also contemplated within the scope of the invention. Chimeric antibody molecules can include, for example, the antigen binding domain from an antibody of a mouse, rat, or other species, with human constant regions.

10 Conventional methods may be used to make chimeric antibodies containing the immunoglobulin variable region which recognizes the gene product of SARS-related protein antigens of the invention (See, for example, Morrison et al., Proc. Natl Acad. Sci. U.S.A. 81,6851 (1985); Takeda et al., Nature 314, 452 (1985), Cabilly et al., U.S. Patent No. 4,816,567; Boss et al., U.S.

15 Patent No. 4,816,397; Tanaguchi et al., European Patent Publication EP171496; European Patent Publication 0173494, United Kingdom patent GB 2177096B). It is expected that chimeric antibodies would be less immunogenic in a human subject than the corresponding non-chimeric antibody.

20 Monoclonal or chimeric antibodies specifically reactive with a protein of the invention as described herein can be further humanized by producing human constant region chimeras, in which parts of the variable regions, particularly the conserved framework regions of the antigen-binding domain, are of human origin and only the hypervariable regions are of non-

25 human origin. Such immunoglobulin molecules may be made by techniques known in the art, (e.g., Teng et al., Proc. Natl. Acad. Sci. U.S.A., 80, 7308-7312 (1983); Kozbor et al., Immunology Today, 4, 7279 (1983); Olsson et al., Meth. Enzymol., 92, 3-16 (1982)), and PCT Publication WO92/06193 or EP 0239400). Humanized antibodies can also be commercially produced

30 (Scotgen Limited, 2 Holly Road, Twickenham, Middlesex, Great Britain.)

Specific antibodies, or antibody fragments, such as, but not limited to, single-chain Fv monoclonal antibodies reactive against SARS-

related proteins may also be generated by screening expression libraries encoding immunoglobulin genes, or portions thereof, expressed in bacteria with peptides produced from the nucleic acid molecules of SARS-related proteins. For example, complete Fab fragments, VH regions and FV regions
5 can be expressed in bacteria using phage expression libraries (See for example Ward et al., Nature 341, 544-546: (1989); Huse et al., Science 246, 1275-1281 (1989); and McCafferty et al. Nature 348, 552-554 (1990)). Alternatively, a SCID-hu mouse, for example the model developed by Genpharm, can be used to produce antibodies or fragments thereof.

10 **(b) Diagnostic Assays**

The finding by the present inventors of novel SARS-related proteins allows the development of diagnostic assays for SARS.

In one embodiment of the invention, the SARS-related protein, or functional fragment thereof, can be used in a method to detect antibodies
15 in a sample from patients suspected of having SARS. Accordingly, the present invention provides a method for detecting SARS in a sample comprising contacting the sample with a SARS-related protein which is capable of being detected after it becomes bound to an antibody to SARS-related protein in the sample. These methods include, for example, enzyme
20 linked immunosorbent assay (ELISA), radioimmunoassays (RIA), immunoradiometric assays (IRMA) and immunoenzymatic assays (IEMA). All of these detection methods are well known in the art (for example see US Patent 4,376,110 or US Patent 4,486,530). In this context a "functional fragment" includes a fragment of the SARS-related protein that can bind to
25 antibodies found in a sample taken from a patient infected with coronavirus.

In a specific embodiment, the diagnostic assay will use the nucleocapsid protein, or a fragment thereof, as shown in Figure 1 as the nucleocapsid protein appears to be a major immunogenic antigen of the coronavirus.

30 In another embodiment, a sample from a patient may be assayed for the presence of the SARS-related protein. The SARS-related protein may be detected in a sample using antibodies that bind to the SARS-

related protein which are described in detail in Section II(a). Accordingly, the present invention provides a method for detecting SARS in a sample comprising contacting the sample with an antibody that binds to a SARS-related protein which is capable of being detected after it becomes bound to
5 the SARS-related protein in the sample.

Antibodies specifically reactive with SARS-related proteins, or derivatives thereof, such as enzyme conjugates or labeled derivatives, may be used to detect SARS-related proteins in various biological materials, for example they may be used in any known immunoassays which rely on the
10 binding interaction between an antigenic determinant of SARS-related protein, and the antibodies. Examples of such assays are radioimmunoassays, enzyme immunoassays (e.g. ELISA), immunofluorescence, immunoprecipitation, latex agglutination, hemagglutination and histochemical tests. Thus, the antibodies may be used
15 to detect and quantify SARS-related proteins in a sample in order to determine its role in particular cellular events or pathological states, and to diagnose and treat such pathological states.

Cytochemical techniques known in the art for localizing antigens using light and electron microscopy may be used to detect SARS-related
20 proteins. Generally, an antibody of the invention may be labelled with a detectable substance and SARS-related protein may be localised in tissue based upon the presence of the detectable substance. Examples of detectable substances include various enzymes, fluorescent materials, luminescent materials and radioactive materials. Examples of suitable
25 enzymes include horseradish peroxidase, biotin, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; and
30 examples of suitable radioactive material include radioactive iodine I-125, I-131 or 3-H. Antibodies may also be coupled to electron dense substances,

such as ferritin or colloidal gold, which are readily visualised by electron microscopy.

Indirect methods may also be employed in which the primary antigen-antibody reaction is amplified by the introduction of a second antibody, having specificity for the antibody reactive against the SARS-related protein. By way of example, if the antibody having specificity against the SARS-related protein is a rabbit IgG antibody, the second antibody may be goat anti-rabbit gamma-globulin labelled with a detectable substance as described herein.

Where a radioactive label is used as a detectable substance, the SARS-related protein may be localized by autoradiography. The results of autoradiography may be quantitated by determining the density of particles in the autoradiographs by various optical methods, or by counting the grains.

(c) Modulators of the SARS-related protein

In addition to antibodies described above, other substances that modulate SARS-related protein expression or activity can be identified. Accordingly, the present invention includes the use of the SARS-related proteins to develop or identify substances that modulate SARS-related protein expression or activity. Such substances may be useful in the therapeutic applications to treat SARS which are described below.

(i) Substances that bind SARS-related proteins

Substances that affect SARS-related proteins activity can be identified based on their ability to bind to a SARS-related proteins.

Substances which can bind with the SARS-related proteins of the invention may be identified by reacting the SARS-related proteins with a substance which potentially binds to SARS-related proteins, and assaying for complexes, for free substance, or for non-complexed SARS-related proteins, or for activation of SARS-related proteins. In particular, a yeast two hybrid assay system may be used to identify proteins which interact with SARS-related proteins (Fields, S. and Song, O., 1989, Nature, 340:245-247). Systems of analysis which also may be used include ELISA.

Accordingly, the invention provides a method of identifying substances which can bind with a SARS-related protein, comprising the steps of:

(a) reacting a SARS-related protein and a test substance, under
5 conditions which allow for formation of a complex between the SARS-related proteins and the test substance, and

(b) assaying for complexes of a SARS-related protein and the test substance, for free substance or for non complexed a SARS-related protein, wherein the presence of complexes indicates that the test substance
10 is capable of binding a SARS-related protein.

The SARS-related proteins used in the assay may have the amino acid sequence shown in Figure 1 or 2 or may be a fragment, analog, derivative, homolog or mimetic thereof as described herein.

Conditions which permit the formation of substance and SARS-
15 related protein complexes may be selected having regard to factors such as the nature and amounts of the substance and the protein.

The substance-protein complex, free substance or non-complexed proteins may be isolated by conventional isolation techniques, for example, salting out, chromatography, electrophoresis, gel filtration,
20 fractionation, absorption, polyacrylamide gel electrophoresis, agglutination, or combinations thereof. To facilitate the assay of the components, antibody against a SARS-related protein or the substance, or labelled SARS-related protein, or a labelled substance may be utilized. The antibodies, proteins, or substances may be labelled with a detectable substance as described above.

25 The SARS-related protein, or the substance used in the method of the invention may be insolubilized. For example, the SARS-related protein or substance may be bound to a suitable carrier. Examples of suitable carriers are agarose, cellulose, dextran, Sephadex, Sepharose, carboxymethyl cellulose polystyrene, filter paper, ion-exchange resin, plastic
30 film, plastic tube, glass beads, polyamine-methyl vinyl-ether-maleic acid copolymer, amino acid copolymer, ethylene-maleic acid copolymer, nylon,

silk, etc. The carrier may be in the shape of, for example, a tube, test plate, beads, disc, sphere etc.

The insolubilized protein or substance may be prepared by reacting the material with a suitable insoluble carrier using known chemical
5 or physical methods, for example, cyanogen bromide coupling.

The proteins or substance may also be expressed on the surface of a cell using the methods described herein.

The invention also contemplates assaying for an antagonist or agonist of the action of a SARS-related protein.

10 (ii) Peptide Mimetics

The present invention also includes peptide mimetics of the SARS-related proteins of the invention. For example, a peptide derived from a binding domain of a SARS-related protein will interact directly or indirectly with an associated molecule in such a way as to mimic the native binding
15 domain. Such peptides may include competitive inhibitors, enhancers, peptide mimetics, and the like. All of these peptides as well as molecules substantially homologous, complementary or otherwise functionally or structurally equivalent to these peptides may be used for purposes of the present invention.

20 "Peptide mimetics" are structures which serve as substitutes for peptides in interactions between molecules (See Morgan et al (1989), Ann. Reports Med. Chem. 24:243-252 for a review). Peptide mimetics include synthetic structures which may or may not contain amino acids and/or peptide bonds but retain the structural and functional features of a peptide, or
25 enhancer or inhibitor of the invention. Peptide mimetics also include peptoids, oligopeptoids (Simon et al (1972) Proc. Natl. Acad. Sci USA 89:9367); and peptide libraries containing peptides of a designed length representing all possible sequences of amino acids corresponding to a peptide of the invention.

30 Peptide mimetics may be designed based on information obtained by systematic replacement of L-amino acids by D-amino acids, replacement of side chains with groups having different electronic properties,

and by systematic replacement of peptide bonds with amide bond replacements. Local conformational constraints can also be introduced to determine conformational requirements for activity of a candidate peptide mimetic. The mimetics may include isosteric amide bonds, or D-amino acids
5 to stabilize or promote reverse turn conformations and to help stabilize the molecule. Cyclic amino acid analogues may be used to constrain amino acid residues to particular conformational states. The mimetics can also include mimics of inhibitor peptide secondary structures. These structures can model the 3-dimensional orientation of amino acid residues into the known
10 secondary conformations of proteins. Peptoids may also be used which are oligomers of N-substituted amino acids and can be used as motifs for the generation of chemically diverse libraries of novel molecules.

Peptides of the invention may also be used to identify lead compounds for drug development. The structure of the peptides described
15 herein can be readily determined by a number of methods such as NMR and X-ray crystallography. A comparison of the structures of peptides similar in sequence, but differing in the biological activities they elicit in target molecules can provide information about the structure-activity relationship of the target. Information obtained from the examination of structure-activity
20 relationships can be used to design either modified peptides, or other small molecules or lead compounds that can be tested for predicted properties as related to the target molecule. The activity of the lead compounds can be evaluated using assays similar to those described herein.

Information about structure-activity relationships may also be
25 obtained from co-crystallization studies. In these studies, a peptide with a desired activity is crystallized in association with a target molecule, and the X-ray structure of the complex is determined. The structure can then be compared to the structure of the target molecule in its native state, and information from such a comparison may be used to design compounds
30 expected to possess.

(iii) Drug Screening Methods

In accordance with one embodiment, the invention enables a method for screening candidate compounds for their ability to modulate (e.g. increase or decrease) the activity of a SARS-related protein. Such compounds may be useful in treating SARS. The method comprises
5 providing an assay system for assaying SARS-related protein activity, assaying the activity in the presence or absence of the candidate or test compound and determining whether the compound has increased or decreased SARS-related protein activity.

Accordingly, the present invention provides a method for
10 identifying a compound that affects SARS-related protein activity or expression comprising:

(a) incubating a test compound with a SARS-related protein or a nucleic acid encoding a SARS-related protein; and

(b) determining an amount of SARS-related protein activity or
15 expression and comparing with a control (i.e. in the absence of the test substance), wherein a change in the SARS-related protein activity or expression as compared to the control indicates that the test compound has an effect on SARS-related protein activity or expression.

In accordance with a further embodiment, the invention enables
20 a method for screening candidate compounds for their ability to increase or decrease expression of a SARS-related protein. The method comprises putting a cell with a candidate compound, wherein the cell includes a regulatory region of a SARS-related protein gene operably joined to a reporter gene coding region, and detecting a change in expression of the reporter
25 gene.

In one embodiment, the present invention provides culture systems in which cell lines which express the SARS-related protein gene, and thus SARS-related protein products, are incubated with candidate compounds to test their effects on SARS-related protein expression. Such
30 culture systems can be used to identify compounds which upregulate or downregulate SARS-related protein expression or its function, through the interaction with other proteins.

In another embodiment, the present invention provides microchips that have nucleic acid molecules encoding SARS-related protein attached thereto. Such microchips are useful in high throughput screening assays for identifying drugs that interact with SARS-related protein.

5 Such compounds can be selected from protein compounds, chemicals and various drugs that are added to the culture medium. After a period of incubation in the presence of a selected test compound(s), the expression of SARS-related protein can be examined by quantifying the levels of SARS-related protein mRNA using standard Northern blotting
10 procedure, as described in the examples included herein, to determine any changes in expression as a result of the test compound. Cell lines transfected with constructs expressing SARS-related protein can also be used to test the function of compounds developed to modify the protein expression. In addition, transformed cell lines expressing a normal SARS-
15 related protein could be mutagenized by the use of mutagenizing agents to produce an altered phenotype in which the role of mutated SARS-related protein can be studied in order to study structure/function relationships of the protein products and their physiological effects.

 In the identification or design of potential drugs, the biologically
20 active protein SARS-related protein, or fragment thereof, is used to identify small molecules with which they interact in order to fashion drugs which will interfere with the function of the polypeptide *in vivo*. In one approach, one first determines the three dimensional structure of the protein of interest or, for example, of the SARS-related protein receptor or ligand complex, by x-ray
25 crystallography, by computer modelling, or most typically, by a combination of approaches. Less frequently, useful information regarding the structure of the polypeptide can be gained by modelling based on structure of homologous proteins. Thus, by one of these methods, one may design drugs which act as agonists or antagonists of SARS-related protein polypeptide activity. These
30 inhibitors can be small molecules, antibodies, monoclonal antibodies, or antibody fragments. Said inhibitors can therefore then be used to treat SARS and coronavirus mediated diseases.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of specifically binding the SARS-related protein compete with a test compound for binding to the SARS-related protein or fragment thereof. In this manner, the antibodies can be used to detect the presence of any polypeptide which shares one or more antigenic determinants of the SARS-related protein. Antibodies can be prepared according to well known methods (Hurn and Chantler, 1980). A peptide, or a fragment thereof, is generally injected over a several month period into rabbits or other suitable animal. The sera is tested for immunoreactivity to the SARS-related protein, or fragment thereof.

Once a potential drug or SARS-related protein modulator is identified using the above screening assays, it can be tested for therapeutic efficacy in a variety of *in vitro* or *in vivo* models.

(e) Therapeutic Uses

As previously discussed, the SARS-related proteins of the invention were isolated from a patient with SARS and likely are derived from a coronavirus or coronavirus-like virus. Accordingly, the present invention includes the use of SARS-related proteins and modulators thereof in therapeutic applications including the treatment or prevention of conditions associated with coronavirus. The definitions used in this section apply to all embodiments of the invention unless otherwise noted.

In one embodiment, the present invention provides a method of treating or preventing SARS comprising administering to a cell or animal in need thereof, an effective amount of agent that modulates SARS-related protein expression and/or activity. The invention also provides a use of an effective amount of an agent that modulates SARS-related protein expression and/or activity to treat SARS or in the manufacture of a medicament to treat SARS.

The term "agent that modulates SARS-related protein expression and/or activity" means any substance that can alter the expression and/or activity of SARS-related protein and includes agents that can inhibit SARS-related protein expression or activity (SARS-related protein

antagonists) and agents that can enhance SARS-related protein expression or activity (SARS-related protein agonists). The agent can be any type of molecule including, but not limited to, proteins, peptides, nucleic acids (including DNA, RNA, antisense oligonucleotides, peptide nucleic acids),
5 carbohydrates, organic compounds, small molecules, natural products and library extracts. Examples of agents which may be used to modulate SARS-related protein include nucleic acid molecules encoding SARS-related protein; the SARS-related protein as well as fragments, analogs, derivatives or homologs thereof; antibodies; antisense nucleic acids; peptide mimetics;
10 substances isolated using the screening methods described herein.

The term "effective amount" as used herein means an amount effective, at dosages and for periods of time necessary to achieve the desired results.

The term "animal" as used herein includes all members of the
15 animal kingdom, including humans.

The term "treatment or treating" as used herein means an approach for obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions,
20 diminishment of extent of disease, stabilized (i.e. not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. "Treating" can also mean prolonging survival as compared to expected survival if not
25 receiving treatment.

In one embodiment, the invention provides a method of treating or preventing SARS comprising administering an effective amount of a SARS-related protein antagonist. The present invention also provides a use of an effective amount of a SARS-related protein antagonist to treat SARS or
30 in the manufacture of a medicament to treat SARS.

The term "SARS-related protein antagonist" includes any substance that can inhibit the expression of a SARS-related protein gene

and/or the activity of a SARS-related protein. Examples of SARS-related protein antagonists include antibodies as described above.

In a specific embodiment, the antagonist will bind or interfere with the activity of the spike glycoprotein shown in Figure 2.

5 **(f) Pharmaceutical Compositions**

 The above described substances including nucleic acids encoding SARS-related proteins, SARS-related proteins, antibodies, as well as other agents that modulate SARS-related proteins may be formulated into pharmaceutical compositions for administration to subjects in a biologically
10 compatible form suitable for administration *in vivo*. By "biologically compatible form suitable for administration *in vivo*" is meant a form of the substance to be administered in which any toxic effects are outweighed by the therapeutic effects. The substances may be administered to living organisms including humans, and animals.

15 Administration of a therapeutically active amount of pharmaceutical compositions of the present invention is defined as an amount effective, at dosages and for periods of time necessary to achieve the desired result. For example, a therapeutically active amount of a substance may vary according to factors such as the disease state, age, sex, and weight
20 of the individual, and the ability of the substance to elicit a desired response in the individual. Dosage regimes may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.

25 An active substance may be administered in a convenient manner such as by injection (subcutaneous, intravenous, etc.), oral administration, inhalation, transdermal application, or rectal administration. Depending on the route of administration, the active substance may be coated in a material to protect the compound from the action of enzymes,
30 acids and other natural conditions which may inactivate the compound. If the active substance is a nucleic acid encoding a SARS-related protein it may be delivered using techniques known in the art.

The compositions described herein can be prepared by *per se* known methods for the preparation of pharmaceutically acceptable compositions which can be administered to subjects, such that an effective quantity of the active substance is combined in a mixture with a pharmaceutically acceptable vehicle. Suitable vehicles are described, for example, in Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985) or Handbook of Pharmaceutical Additives (compiled by Michael and Irene Ash, Gower Publishing Limited, Aldershot, England (1995)). On this basis, the compositions include, albeit not exclusively, solutions of the substances in association with one or more pharmaceutically acceptable vehicles or diluents, and may be contained in buffered solutions with a suitable pH and/or be iso-osmotic with physiological fluids. In this regard, reference can be made to U.S. Patent No. 5,843,456. As will also be appreciated by those skilled, administration of substances described herein may be by an inactive viral carrier.

(g) Vaccines

The present invention includes vaccines for treating or preventing coronavirus mediated diseases.

In one embodiment, the vaccine comprises a SARS-related protein in admixture with a suitable diluent or carrier. In another embodiment the vaccine comprises a nucleic acid encoding a SARS-related protein in admixture with a suitable diluent or carrier. The term "SARS-related protein" is as previously defined herein to include all homologs, analogs, fragments, or derivatives of the SARS-related protein from coronavirus including the proteins shown in Figures 1 and 2. The fragments of the SARS-related protein will be sufficient in order to elicit an immune response against the coronavirus.

In a specific embodiment, the vaccine will comprise the spike glycoprotein of Figure 2 or a fragment thereof. The spike glycoprotein plays an important role in the initial stages of the infection by mediating the

attachment of the virus to the cell membrane of the host. Consequently, inhibiting or neutralizing this protein may be an effective therapeutic strategy.

In a further embodiment, the vaccine comprises an antibody that binds to a SARS-related protein in admixture with a suitable diluent or
5 carrier. Such antibodies can be prepared as hereinbefore described.

The vaccine can either include a protein (such as a SARS-related protein or antibody that binds a SARS-related protein or peptide) or a nucleic acid encoding the SARS-related protein. Such nucleic acids include free or naked RNA or DNA or in a vector. In a preferred embodiment, the
10 nucleic acid sequence is contained in a vector or plasmid. In one embodiment, the vector may be viral such as poxvirus, adenovirus or alphavirus. Preferably the viral vector is incapable of integration in recipient animal cells. The elements for expression from said vector may include a promoter suitable for expression in recipient animal cells.

15 The vaccines of the invention may be in admixture with a suitable carrier, diluent, or excipient such as sterile water, physiological saline, glucose or the like to form suitable vaccine formulations. The vaccines can also be lyophilized. The vaccines may also contain auxiliary substances such as wetting or emulsifying agents, pH buffering agents,
20 gelling or viscosity enhancing additives, preservatives, flavoring agents, colors, and the like, depending upon the route of administration and the preparation desired. In this regard, reference can be made to U.S. Patent No. 5,843,456. Reference can also be made to the textbook Vaccine Design: the Subunit and Adjuvant Approach, Michael F. Powell and Mark J. Newman,
25 eds. Plenum Press, New York, 1995.

The vaccine may additionally include adjuvants to enhance the immune response to the SARS-related protein or antibody. A wide range of extrinsic adjuvants can provoke potent immune responses to antigens. These include saponins complexed to membrane protein antigens (immune
30 stimulating complexes), pluronic polymers with mineral oil, killed mycobacteria and mineral oil, Freund's complete adjuvant, bacterial products such as

muramyl dipeptide (MDP) and lipopolysaccharide (LPS), as well as lipid A, and liposomes.

Accordingly, the present invention provides a method of eliciting an immune response to coronavirus comprising administering an effective
5 amount of a vaccine formulation comprising a SARS-related protein, a nucleic acid encoding a SARS-related protein or an antibody to a SARS-related protein to an animal in need thereof.

The term "eliciting an immune response" is defined as causing, enhancing, or improving any response of the immune system, for example, of
10 either a humoral or cell-mediated nature. Whether a vaccine or antigen elicits an immune response can be assessed using assays known to those skilled in the art including, but not limited to, antibody assays (for example ELISA assays), antigen specific cytotoxicity assays and the production of cytokines (for example ELISPOT assays).

15 The term "administering" is defined as any conventional route for administering an antigen to an animal for use in the vaccine field as is known to one skilled in the art. This may include, for example, administration via the topical, oral and parenteral (i.e. subcutaneous, intradermal, intramuscular, etc.) routes and further includes, transdermal and mucosal
20 delivery, including mucosal delivery accomplished by oral feeding, inhaling and through the membranes accessible through the terminal portions of the large intestine.

Also provided are kits for carrying out the SARS detection assays discussed above. For example, such kits may include any one or
25 more of the following: an isolated SARS-related polypeptide, one or more antibodies specific to a SARS-related polypeptide, a detection label and instructions for using the kit. As will be appreciated by one of skill in the art, other suitable components and reagents may also be included. It is of note that the above-described kit may be used for detecting the presence of anti-
30 SARS antibodies in a sample (using labeled isolated SARS-related polypeptide or immunogenic fragments thereof) or for detecting the presence of SARS-related polypeptides.

The following non-limiting examples are illustrative of the present invention:

EXAMPLE 1

EXPERIMENTAL PROCEDURES

5 **Discovery and Isolation of SARS coronavirus**

SARs coronavirus was grown in Vero E6 cell culture using Minimal Essential Medium (designated MEM) supplemented with antibiotics, fungizone, amino acids, vitamins, HEPES buffer and 3% fetal calf serum. Medium was stored at 4°C.

10 Confluent monolayers of Vero-E6 cells grown in culture tubes were inoculated with patient respiratory secretion specimens were incubated at 37°C and examined under an inverted microscope daily. Observation of a cytopathic effect in some of the inoculated cultures (as compared to normal healthy cells) indicated the possibility of virus growth.

15 All bacteriology was negative. Identification of the virus as a new coronavirus was done by PCR tests for most known families of viruses. This excluded many agents as the cause of disease, especially viruses or bacteria known to be associated with pneumonia. However, there was a positive reaction for coronavirus 5 out of 8 of the initial cluster of SARS. Sequencing
20 of the PCR products gave a sequence confirming that a coronavirus was the probable aetiological agent, and that the SARS coronavirus is a new family of virus that is distantly related to previously known human and animal coronaviruses. Employing the Vero-E6 grown SARS coronavirus antigen, serological tests (ELISA and IFA) to detect the presence of antibodies in
25 patients were developed. Employing these methods, further testing confirmed the SARS coronavirus as the cause of the disease. In more than 250 suspect or probable SARS cases, 95% tested positive for this new coronavirus.

30 **Nucleocapsid isolations, RNA purification and extraction from SARS coronavirus:**

- Vero E6 cells were inoculated with SARS coronavirus at a multiplicity of between 1 and 5 infectious units per cell. When approximately 80% of the SARS CoV infected cells showed CPE (3 days post-infection), they were harvested for viral nucleocapsid isolation. The SARS CoV nucleocapsids
- 5 were isolated from infected cells as follows. Briefly, 10^7 infected cells were lysed in 6mL lysis buffer (0.5% deoxycholate, 0.5% NP-40, 30mM Tris pH 7.5, 5mM $Mg(C_2H_3O_2)_2 \cdot 4H_2O$, 125mM KCl, 0.5mM EDTA, 3.6mM $CaCl_2$, 6mM 2-mercaptoethanol) and sonicated (Branson Sonifier 250) on ice at 50% power for 10, 10 second bursts. Cell lysis was confirmed by light microscopy
- 10 on a hemocytometer. 600 units of DNase I (Invitrogen, Burlington, Ontario) and 6µl of 10mg/mL RNase A (Sigma, Oakville, Ontario) were added and the mixture was incubated at 30C for 90 minutes with 600 units of DNase I added every 30 minutes. 6mL of 1,1,2-trichloro-trifluoroethane (Sigma, Oakville, Ontario) was added and mixed vigorously before centrifugation at 800 xg for
- 15 10 minutes. The top fraction was removed and ultracentrifuged (Beckman Optima XL-100K) through a 5 to 40% glycerol gradient in lysis buffer at 151,000 xg for 1 hour at 4C. The RNA was then extracted from the nucleocapsid preparation using Qiagen's RNeasy Kit as follows:
- 20
1. Resuspend pellet in 100 µl PBS and add to 350 µl RTL (with beta-mercaptoethanol.) for RNA extraction and polyA RNA) for RNA extraction.
 2. Add 450 µl 70% EtOH and vortex.
 3. Attach purification column to vacuum manifold and set vacuum to 600

25 psi)

 4. Add sample to column and apply vacuum until the entire sample has passed through
 5. add 700 µl RW1 buffer and apply vacuum.
 6. Add 500 µl RPE buffer and apply vacuum

30

 7. Add 500 µl RPE buffer and apply vacuum (i.e. 2 washes)
 8. Transfer column to a collection tube and centrifuge for 2 min. at 10 K rpm to remove traces of RPE.

9. Transfer column to 1.5 ml eppendorf tube, and add 50 ul DEPC water to the column membrane. Let stand 1 min.
10. Centrifuge for 1 min. at 10 K rpm and store RNA at -70C for later use in sequencing. The purity and yield of the viral RNA was confirmed by
- 5 checked by spectrophotometry

VERO E6 Cell Growth Media

Reagents:

- Fetal Bovine Serum Gibco Cat #16000-044
- 10 Minimum Essential Medium (MEM) with Earle's salts, without L-glutamine
Gibco BRL Cat# 11090-081
- Penicillin-Streptomycin-Glutamine 100x, liquid (10,000 U/ml penicillin G;
10,000 ug/ml
streptomycin sulfate and 29.2 mg. of L-Glutamine) Gibco BRL Cat# 10378-
- 15 057
- HEPES Buffer, 1M stock solution Gibco BRL Cat# 15630-080
- MEM Sodium Pyruvate Solution 100 mM (100x), liquid Gibco BRL Cat#
11360-070
- MEM Non-Essential Amino Acids Solution 10mM (100 x), liquid Gibco BRL
- 20 Cat# 11140-050

To prepare 500 ml of cell growth media:

	<u>Reagent</u>	<u>Volume</u>	<u>Final Concentration</u>
25	Fetal Calf Serum	50 ml	10%
	Penicillin-Streptomycin-	5.0 ml	100 U/ml
	Penicillin and		
	Glutamine		100 ug/ml
	Streptomycin		
30			.292 mg/ml
	Glutamine		
	HEPES buffer	12.5 ml	25 mM

MEM Non essential AA	5 ml	0.1 mM
MEM Sodium pyruvate	5 ml	1.0 mM

Preparation of the Primary Material at NML – As discussed
5 above, clinical specimens obtained from the original case cluster were
extensively investigated for the presence of bacterial and viral pathogens (1).
Nasopharyngeal swab and bronchoalveolar lavage fluids from several of
these patients were found to be positive by reverse transcription-polymerase
chain reaction (RT-PCR) for human metapneumovirus and the novel
10 coronavirus (1). Inoculation of the bronchoalveolar lavage fluid from the 43-
year-old male patient in Vero E6 cells produced a strong cytopathic effect on
day four after infection. The second passage of this viral isolate was further
used to produce large quantities of the virus. Initially this virus material was
used to assess its antigenicity with convalescent serum samples from SARS
15 patients. The convalescent sera that were previously found to be positive for
antibodies to the virus by indirect immunofluorescence assay (IFA) (11)
strongly reacted in Western blot with a ~46 kDa protein (Fig. 3A) similar in
size to the nucleocapsid protein of coronaviruses (12).

In order to prepare this, (and perhaps other SARS-related
20 proteins) for proteolytic digestion, the virus was purified by 20-60% linear
sucrose gradient. Western blotting of the gradient fractions showed that
fraction #4 (density 1.18g/cm³) reacted strongly with a convalescent serum
from a SARS patient. This fraction was run on SDS-PAGE and stained with
Coomassie blue (Fig. 3B), then excised and transferred to the University
25 laboratories for digestion with various proteolytic enzymes.

Proteolytic Digestions - The excised protein bands were in-gel digested with
one of three different enzymes [sequencing grade modified trypsin
(Promega), Lys-C, or Asp-N (both from Roche Biochemical)]. Digestions were
performed according to the procedure described by Shevchenko et al (13)
30 either in H₂¹⁶O, or in a 1:1 H₂¹⁶O:H₂¹⁸O mixture (14–16), prepared from 98%
H₂¹⁸O (Isotec). Unless otherwise noted, all other chemicals were purchased
from Sigma.

The extracts containing the peptide mixture were lyophilized and resuspended in 5.5 ml of 0.5 % TFA in water. 0.5 ml of the resulting sample was mixed 1:1 with 2,5-dihydroxybenzoic acid (DHB, 150 mg/ml in water:acetonitrile 1:1) matrix solution, and deposited on the gold surface of a MALDI target. The remaining 5 ml was used for mHPLC–MALDI –QqTOF analysis.

Chromatography - Chromatographic separations were performed using an Agilent 1100 Series system. Deionized (18 MΩ) water and HPLC-grade acetonitrile were used for the preparation of eluents. Samples (5 µl) were injected onto a 150mm × 150 mm column (Vydac 218 TP C18, 5m) and eluted with a linear gradient of 1-80% acetonitrile (0.1% TFA) in 60 min. The column effluent (4 ml/min) was mixed on-line with DHB matrix solution (0.5 µl/min) and deposited by a small computer-controlled robot onto a movable gold target at 1 min intervals (17). The vast majority of the tryptic fragments were eluted within 40 min under the HPLC condition used, so 40 fractions were normally collected.

Glycoprotein Analysis - The original intention was to postpone any detailed analysis of the higher mass protein to a subsequent investigation. When the inventors decided to include this effort in the present measurements, the only materials that they had available were two lyophilized samples from digests of the larger protein (~180 kDa band), one from a tryptic digest and one from a Lys–C digest. The sample from the tryptic digest was separated by HPLC and used for analysis of the glycosylated peptides. The sample from the Lys–C digest was digested twice more, first by pNGase F (Roche Biochemical) to remove the sugars, then by trypsin to produce smaller fragments, (both digestions in H₂¹⁶O).

Time-of-flight Mass Spectrometry - The spots on the gold targets were analyzed individually, both by single mass spectrometry (MS) and by tandem mass spectrometry (MS/MS) in the Manitoba/Sciex prototype quadrupole/time-of-flight mass spectrometer (QqTOF) (18). Ions were produced by irradiation of the target with photon pulses from a 20-Hz nitrogen laser (Laser Science) with 300 mJ energy per pulse. Orthogonal injection of

ions from the quadrupole into the TOF section normally produced a mass resolving power 10,000 FWHM and accuracy within a few mDa in the TOF instrument for both MS and MS/MS spectra, as long as the ion peak was reasonably intense.

5 RESULTS

Mass spectra from proteolytic digests of the ~47-kDa Protein –

Figure 4A shows the m/z spectrum of the mixture of peptides resulting from tryptic digestion of the ~47-kDa protein in $H_2^{16}O$, before HPLC fractionation. A small region of this spectrum is shown in Fig. 4B, and an HPLC fraction
10 showing some of the same ions is shown in Fig. 4C. Here the most intense ion in Fig. 5B has moved to a different fraction, but some of the weaker ions are much more prominent, so it is clear that individual peptide peaks are considerably easier to distinguish after HPLC separation. Spectra of the fractions are dramatically simpler and have a signal/noise ratio improved by a
15 factor ~10 or more.

Initial efforts to identify the protein, (based on database searching against the peptide fingerprint), failed to yield any significant matches, suggesting that it was a novel protein. *De novo* peptide sequencing was therefore undertaken in order to characterize it. For this purpose,
20 samples were digested in the presence of a 50/50 mixture of $H_2^{16}O$ and $H_2^{18}O$, as described above, since the addition of ^{18}O or ^{16}O during enzymatic cleavage identifies fragments containing the C-terminus by their distinctive isotopic patterns (14-16). In order to determine the amino acid sequence of the proteolytic fragments, each clearly observed peptide ion was selected in
25 turn as a parent by the mass-selecting quadrupole of the QqTOF instrument, and subjected to collisionally-induced dissociation in the collision cell. For example, the resulting daughter ion spectrum from the $m/z = 2297$ parent is shown in Fig. 5, where the advantages of the $^{16}O/^{18}O$ addition for distinguishing the C- and N-terminal ions are clearly evident. The y ions,
30 which contain the C-terminus, all show the doublet structure superimposed on the usual isotopic pattern, whereas the b ions, containing the N-terminus,

have a normal pattern. A comparison between the measured m/z values and the masses calculated from the deduced sequence is given in Table 1.

Further examples are provided in the supplemental material. Fig. 8 shows the daughter ions from dissociation of the 1144 Da N-terminal peptide, indicating deletion of the N-terminal methionine and acetylation of the resulting N-terminal serine. Fig. 9 shows a comparison between the daughters of HPLC-separated parents of masses 1411 and 1795 Da, from tryptic and Lys-C digestions respectively. Fig. 10 shows a spectrum of the parent ion containing the C-terminus— the one C-terminal peptide that shows no doublet structure.

A comparison of experimental m/z values and masses calculated for the deduced sequences of all the peptides observed in tryptic digests is given in Table 2. In both tables 1 and 2, most observed m/z values and the masses calculated for the deduced amino acid sequences agree within ~10 mDa, lending credibility to the assignments; the anomalously high values observed for a few ions in Table 1 correspond to peaks of very low intensity.

The MS and MS/MS measurements just described were applied first to the peptides resulting from tryptic digests of the gel band, listed in Table 1, and then to the products of a Lys-C digest. BLAST searching (20, 21) of the total Genbank protein database with these peptides was then undertaken in order to search for homology. The most definitive example was provided by the 2297 Da tryptic peptide. In that case, the highest rated results of the BLAST search are shown in Fig. 6; all are coronavirus nucleocapsid proteins, and all yield BLAST scores of 40 to 41, with E values 0.003. Moreover, the highest rated hit in the BLAST search that is not a coronavirus protein had a score of only 29 and a high E value of 9.4. Thus the ~47 kDa protein is clearly a coronavirus nucleocapsid protein; there is complete agreement between the first 10 residues and those found by BLAST in a region of the coronaviruses that is highly conserved. On the other hand, only 3 out of the next 9 residues agree with any of the other viruses, so the SARS virus is significantly different from any of the other coronaviruses.. BLAST

searches with the other peptides strengthened the evidence for significant differences between the SARS coronavirus and any other coronavirus in the database, but led to similar conclusions.

By April 12 these measurements had been carried out and most
5 of them analyzed, yielding almost complete sequence information on the individual peptides, as summarized in Table 2. The task of fitting together the peptides was not yet done, however, since there were still a number of ambiguities in their order. To sort out this problem, an Asp-N digestion had also been carried out, (but not yet separated on the HPLC), and Glu-C and
10 perhaps Arg-C digestions were planned as soon as sufficient material was available. More sophisticated BLAST searches (20) were also planned. However, these measurements and analyses turned out to be unnecessary, because at that stage a nucleotide sequence of infectious material, (also prepared by NML), was obtained by a group at the Michael Smith Genome
15 Centre in Vancouver (Genbank database accession AY274119), soon followed by similar results from several other laboratories.

It soon became clear to us that the open reading frame identified by the Vancouver group as specifying the coronavirus nucleocapsid protein did in fact predict the aa sequence of the ~47 kDa protein that we
20 were analyzing, so we were able to remove the remaining ambiguities in ordering the proteolytic fragments listed in Table 2. A comparison of our results with the predicted sequence is shown in Fig. 11A; our mass spectral data cover more than 96% of the predicted sequence, and include both C- and N-termini. The mass spectra also indicate removal of the N-terminal
25 methionine, and oxidation of all other methionines, as well as acetylation of the resulting N-terminal serine, as shown in Fig. 8. The N-terminal deletion and acetylation presumably occur as a result of post-translational modifications, which of course could not be predicted by the nucleotide data. Otherwise, our results are in complete agreement with the predicted
30 sequence (Genbank database accession AY274119), a result consistent with the samples being derived from the same infectious source at NML.

Mass spectra from proteolytic digests of the Spike Protein - In addition to the almost completely defined ~47 kDa protein, we have partially characterized a protein that appeared as a very weak band at an apparent mass ~180 kDa in the gel separation (Fig. 3B). In spite of the low intensity, 39 peptides in the initial tryptic digest were found to belong to the ~139 kDa "spike protein" predicted by the nucleotide sequence (Genbank database accession AY274119), and 36 of these were sufficiently intense for MS/MS measurements, which confirmed the identification (30% coverage). A summary of the data and the coverage for this protein is given in Table 5.

This protein is homologous to spike proteins in other coronaviruses, which are reputed to be extensively glycosylated, and to act as attachment proteins. Indeed, the predicted sequence of the spike protein of the SARS coronavirus contains 23 potential N-glycosylation sites (NXT or NXS), of which 17 are identified as likely sites by the Netglyc 1.0 server (21). (O-glycosylation may also be possible, but has not been investigated here).

A tryptic digest of the spike protein was therefore treated with PNGase F to remove the glycans, as described above. This step converts asparagine residues to aspartic acids, thus specifying the corresponding deglycosylated peptides through observation of their mass differences of 0.984 Da per deglycosylated site from the values calculated from the predicted aa sequence. This procedure identified 9 glycopeptides and their deglycosylated products (Table 3), and raised the sequence coverage to 42%. MS/MS measurements on all deglycosylated peptides confirmed the predicted single N-glycosylation sites, and T111-126, T316-333 and T1140-1163 were found to have two glycosylation sites each (Table 3). For example, figure S5 shows MS and MS/MS spectra of the deglycosylated peptide T222-232. No peptides were observed containing possible sites that were *not* glycosylated, suggesting that some of the other sites may also be modified by glycosylation.

The tryptic digest of the spike protein without PNGase F deglycosylation yielded spectra of four of these glycopeptides that were sufficiently intense for detailed analysis, as summarized in Table 4.

Microheterogeneity was observed in all four glycopeptides, and each glycoform was assigned an N-linked glycan composition. Two peptides, T222-232 and T778-796, were found to have high-mannose substitution M_xN_y , whereas the other two (T111-126, T226-287) showed complex glycan structures $M_xN_yG_zF$; (M=mannose, N=N-acetyl glucosamine, G=galactose, F=fucose), similar to the pattern observed in the bovine coronavirus hemagglutinin protein (22). These compositions each encompass more than one isomeric structure; some examples are given in Figure 7D. It is important to note that some observed glycoforms may result from in-source fragmentation, although the results suggest that this is improbable (see below).

Figure 7A shows the MALDI mass spectrum of the HPLC fraction containing glycosylated T111-126. This spectrum is interpreted in Table 3 as containing either one or two O-glycosylation sites; whereas peaks between m/z 3000 and 3800 show one possible glycosylation site, those higher than m/z 3800 possibly correspond to di-glycosylated T111-126 (see Fig. 5D). In Fig. 5B, MS of the glycosylated T222-232 HPLC fraction clearly highlights the presence of high mannose structures. Here the predominance of M_2N_9 , the highest possible form of N-linked high mannose oligosaccharide, suggests that there is little in-source fragmentation. Figure 7C is the tandem mass spectrum of T222-232 with an M_9N_2 attachment. This spectrum shows losses of one to five mannose residues, loss of the whole oligosaccharide moiety (m/z 1257.733), loss of the whole moiety minus one N (m/z 1460.808), and loss of the carbohydrate residue via a cross-ring cleavage (m/z 1340.768). MS/MS analysis of m/z 3404.572, 3607.682 and 4093.818 ions confirmed the presence of complex glycan structures from observed losses of [G-N] moieties (not shown). Tandem MS was also performed on glycoforms of T226-287 and T778-796, with results consistent with the suggested complex glycan compositions in Table 4 (spectra not shown). All MS/MS spectra recorded in this study showed that the preferred fragmentation mode was loss of the entire sugar rather than loss of one

residue at a time, which again argues against extensive in-source fragmentation.

Other candidate peptides were sought in their possible glycosylated forms but were not detected, perhaps because of the low amount of sample. Alternatively, they may not be detectable as *positive ions* because of the presence of negatively charged sialic acids. Indeed, the several galactosylated complex oligosaccharide compositions found in this study suggest the undetected presence of sialic acid, since the latter compound attaches to terminal galactose in such structures.

10 DISCUSSION

The nucleocapsid protein N - Comparison of deduced amino acid sequences of different coronavirus N proteins revealed 32% identity between the SARS-related coronavirus and known viruses from the three coronavirus clusters. The phylogenetic tree (23) of the N protein-deduced amino acid sequences indicated that the SARS-related virus is only distantly related to any of the other clusters (Fig. 11B). The evolutionary distance, based on this phylogenetic tree analysis, makes it difficult to speculate about the origin of the virus.

Despite the striking heterogeneity of the SARS corona N protein when compared with other corona nucleoproteins certain domains seem functionally conserved (24). The SR-rich region of SARS N protein resembles that of murine and bovine corona viruses; in a short stretch of 36 residues (amino acids 176-212) it contains 14 serines and 7 arginines. The amino acid sequence in this region is highly variable among coronaviruses except for a core motif SRXX for which double or triple repeats are a distinguishable feature among all coronavirus N proteins. This region has been mapped as the RNA binding domain of the N protein. An intriguing feature of SARS N protein is that it contains five SRXX motifs (Fig. 11A, see highlighted aa sequence); whether that will translate into much higher RNA-binding activity remains to be seen. However, this finding supports the concept of a conserved function within the SR-rich domain.

The appearance of a shorter form of the N-protein late in infection has been observed with TGEV, MHV, FIPV, BCV, avian IBV & TCV coronaviruses (~2 to 5kDa less) in cell culture. It has been demonstrated that host cell caspases, which are activated during coronavirus infection, are responsible for this cleavage (25). A common caspase cleavage motif is present in all of the mentioned coronavirus N proteins. Furthermore the accumulation of the shortened N protein form was correlated with a 2 log fold reduction in virus production. These observation suggest that cleavage of viral nucleocapsid protein by host cell caspases could be a general mechanism by which infected cells eliminate coronaviruses. Interestingly, no caspase cleavage motif is present in the SARS related coronavirus N-protein.

The spike protein S - The spike protein is a major target of the cellular immune response to coronaviruses, and plays an important role in the initial stages of infection. It mediates the attachment of the virus to the cell surface receptors and induces the fusion of the viral and cellular membranes. With several types of viruses, the importance of N-glycosylation on attachment proteins has often been highlighted in virus-receptor interactions.

In influenza C and A viruses, which are myxoviruses, Rosenthal et al. showed that N-glycosylation of the hemagglutinin-esterase-fusion proteins can have dramatic effects on immune escape, virulence, and interactions with cellular receptors (26). The hemagglutinins have been shown to interact with sialic acid moieties on the receptors, and it is known that neuraminidase inhibitors inhibit the replication of influenzaviruses A and B (27)

Hepatitis viruses have been shown to bud into the ER and depend on N-glycosylation of coat proteins to form infectious virus particles (28, 29). Dwek and his colleagues investigated the effect of deoxynojirimycin, an alpha-glucosidase inhibitor, and found that it would block oligosaccharide processing at the stage of monoglucosylation of Asn sites. The glucosylated proteins were shown to misfold. Even at very low inhibitor concentration, viral titers dropped by nearly 100-fold (30). Studies in animals showed that deoxynojirimycin had a negligible effect on host glycosylation (31) and thus

drugs such as this alpha-glucosidase inhibitor are seen as good candidates for treatment of hepatitis B. Hepatitis C virus may also respond to these inhibitors (32). Similar studies using sugar inhibitors on HIV, which has many N-linked sites, but showed less sensitivity to misglycosylation (33).

5 Rossen and co-workers modified the N-glycosylation characteristics of coronavirus spike proteins in cultured epithelial cells, and found that N-glycans had an important impact virus formation and behaviour. For example, inhibition of spike N-glycosylation by tunicamycin, which inhibits the synthesis of N-glycans, resulted in the synthesis of spikeless virions,
10 which however still had the capacity of releasing virions (34). The same authors also discussed the implications of N-glycosylation of hemagglutinin proteins of epithelial cell coronaviruses (34).

 The SARS-associated coronavirus genome sequence shows that it does not contain a gene encoding hemagglutinin or large genes derived
15 from another virus or host cell (35). It is believed that host range, tissue tropism, and virulence of animal coronaviruses can be changed by mutating the S gene, thus modifying the S proteins (35).

 Although no drugs with proven efficacy are currently approved against coronaviruses, potential targets exist for new drugs. For example,
20 protease inhibitors could prevent processing of the RNA polymerase or cleavage of the viral S glycoprotein. Finding antibodies against the S glycoprotein or against the unidentified SARS coronavirus receptor are possible routes to take (35). Also, the use of glycosylation inhibitors which have minimal effects on host cells would be an interesting avenue (30). Very
25 recently, an important contribution by Hilgenfeld et al. (36) outlined a plan for drug design based on inhibition of the viral main proteinase, called M pro or 3CL pro, which controls the activities of the coronavirus replication complex (36).

 Ideas for development of vaccines against SARS include the
30 use of killed or subunit vaccines containing the spike glycoprotein with other viral proteins.

Summation - The present studies provide the first descriptions of proteins derived from the novel coronavirus thought to be the etiologic agent of SARS. Similar to the pattern observed with animal coronaviruses (21), the 46 kDa nucleoprotein appears to be the major immunogenic antigen, as it was the only viral protein recognised by acute and early convalescent sera from several patients recovering from SARS. While the immune response to the NP could serve as an early diagnostic marker for infection, it is unlikely that an immune response to this protein offers protection, since it is an internal protein and neutralizing antibodies are more likely to target the surface proteins (6). However, it has been shown for other coronaviruses that some antigenic peptides of the N protein can be recognized on the surface of infected cells by T cells (6).

The application of *de novo* sequencing by mass spectrometry provides an alternative to the usual genomic approach for protein identification. Thus it was possible to identify the 46 kDa protein as a novel coronavirus nucleocapsid protein even in the absence of initial genomic sequence. It also provided unequivocal characterization of the proteins produced, including the definition of post-translational modifications. However, perhaps its most important contribution is to distinguish the actual proteins expressed from those that are simply hypothesized or predicted by the nucleotide sequence.

While the present invention has been described with reference to what are presently considered to be a preferred example, it is to be understood that the invention is not limited to the disclosed example. To the contrary, the invention is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims.

All publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

**FULL CITATIONS FOR REFERENCES REFERRED TO IN THE
SPECIFICATION**

1. Poutanen, S. M. et al. (2003) Identification of severe acute
5 respiratory syndrome in Canada. *N Engl. J. Med.* 348:1995-2005
2. Booth, C. M. et al, (2003) Clinical features and short-term
outcomes of 144 patients with SARS in the greater Toronto area. *JAMA* May
6, [epub. ahead of print]
3. Marra, M. A. et al, (2003) The genome sequence of the SARS-
10 associated coronavirus. *Science* May 1, [epub. ahead of print]
4. Rota, P. A. et al, (2003) Characterization of a novel coronavirus
associated with severe acute respiratory syndrome. *Science* May 1, [epub.
ahead of print]
5. Thomas, J. J., R. Bakhtiar, R., G. Siuzdak, G. (2001) Mass
15 spectrometry in viral proteomics. *Acc. Chem. Res.* 33, 179-187
6. Seifers, D. L., Harvey, T. L., Haber, S., She, Y-M.,
Chernushevich, I., Ens, W., and Standing, K. G. (1999) Natural infection of
sorghum by foxtail mosaic disease in Kansas. *Plant Disease* 83, 905-912
7. Seifers, D. L., Salomon, R., Marie-Jeanne, V., Alliot, B.,
20 Signoret, P., Haber, S., Loboda, A., Ens, W., She, Y-M., and Standing, K. G.
(2000) Characterization of a novel potyvirus isolated from maize in Israel,
Phytopathology 90, 505-513.
8. She, Y-M, Haber, S., Seifers, D. L., Loboda, A., Chernushevich,
I., Perreault, H., Ens, W., and Standing, K. G. (2001) Determination of the
25 complete amino acid sequence for the coat protein of brome mosaic virus by
time-of-flight mass spectrometry, *J. Biol. Chem.* 276, 20039-20047.
9. Swanson, M. I., She, Y-M, Ens, W., Brown, E. G., and Coombs,
K. M. (2002) Mammalian reovirus core protein micro 2 initiates at the first start
codon and is acetylated. *Rapid Commun. Mass Spectrom.* 16, 2317-2324.
- 30 10. Mendez, I. I., She, Y. M., Ens, W., and Coombs, K. M. (2003)
Digestion pattern of reovirus outer capsid protein s3 determined by mass
spectrometry. *Virology*, in press.

11. Li, Y., unpublished.
12. Lai, M. M. C., Holmes, K. V. (2001) in *Fields Virology* (4th ed), pp. 1163-1185.
13. Shevchenko, A., Wilm, M., Vorm, O., and Mann, M. (1996)
- 5 Mass spectrometric sequencing of proteins from polyacrylamide gels. *Anal. Chem.* 68, 850-858.
14. Shevchenko, A., Chernushevich, I., Ens, W., Standing, K. G., Thomson, B., Wilm, M., and Mann, M. (1997) Rapid 'de novo' peptide
- 10 sequencing by a combination of nanoelectrospray, isotopic labeling and a quadrupole/time-of-flight mass spectrometer. *Rapid Commun. Mass Spectrom.* 11, 1015-1024.
15. Stewart, II, Thomson, T., and Figeys, D. (2001) 18O labeling: a tool for proteomics. *Rapid Commun. Mass Spectrom.* 15, 2456-2465.
- 15 16. Yao, X., Alfonso, C., and Fenselau C. (2003) Dissection of proteolytic 18O labeling: endoprotease catalyzed 16O to 18O exchange of truncated peptide substrates. *J. Proteome Res.* 2, 147-152.
17. Krokhin, O., Qian, Y., McNabb, J. R., Spicer, V., Standing, K. G., and Ens, W. (2002) An off-line interface between HPLC and orthogonal
- 20 MALDI TOF. *Am. Soc. for Mass Spectrometry, 50 th ASMS Conference on Mass Spectrometry and Allied Topics, Orlando FL USA, 2-6 June: paper WPP 233.*
18. Loboda, A. V., Krutchinsky, A. N., Bromirski, M., Ens, W., and Standing, K. G. (2000). A tandem quadrupole/time-of-flight mass
- 25 spectrometer with a matrix-assisted laser desorption/ionization source: design and performance. *Rapid Commun. Mass Spectrom.* 14, 1047-1057.
19. Altschul, S. F., Stephen, F., Madden, T. L., Schaeffer, Zhang, J., Miller, W., and Lipman, D. J. (1997). Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res.* 25,
- 30 3389-3402.
20. A. Shevchenko, A., Loboda, A., Sunyaev, S., Shevchenko, A., Bork, P., Ens, W., and Standing, K. G. (2001). Charting the proteomes of

- organisms with unsequenced genomes by MALDI-quadrupole time-of-flight mass spectrometry and BLAST homology searching. *Anal. Chem.* 73, 1917-1926.
21. NetNglyc 1.0 server: <http://www.cbs.dtu.dk/services/NetNGlyc/>
- 5 22. Hogue, B. G., and Brian, D. A. (1987). Glycosylation of the bovine coronavirus hemagglutinin protein. *Adv. Exp. Med. Biol.* 218, 131-136
23. Thompson, J. D., Higgins, D. G., Gibson, T. J. (1994). CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties, and
- 10 weight matrix choice. *Nucleic Acids Res.* 22, 4673-4680.
24. Nelson, G. W., Stohlman, S.A., Tahara, S.M. (2000). High affinity interaction between nucleocapsid protein and leader/intergenic sequence of mouse hepatitis virus RNA. *J Gen Virol.* 81,181-188.
25. Eleouet, J. F., Slee, E. A., Saurini, F., Castagne, N., Poncet, D.,
- 15 Garrido, C., Solary, E, and Martin S. J. (2000). The viral nucleocapsid protein of transmissible gastroenteritis coronavirus (TGEV) is cleaved by caspase-6 and -7 during TGEV-induced apoptosis. *J Virol.* 74, 3975-3983.
26. Rosenthal, P.B., Zhang, X., Formanowski, F., Fitz, W., Wong, C. H., Meier-Ewert, H., Skehel, J. J., and Wiley, D. C. (1998) Structure of the
- 20 haemagglutinin-esterase-fusion glycoprotein of influenza C virus. *Nature* 396 92-96.
27. Oxford, J. S., Bossuyt, S., Balasingam, S., Mann, A., Novelli, P., Lambkin, R. (2003). *Clin Microbiol Infect.* 9, 1-14.
28. Lu, X., Mehta, A., Dwek, R., Butters, T., Block, T. (1995).
- 25 Evidence that N-linked glycosylation is necessary for hepatitis B virus secretion. *Virology* 213, 660-665.
29. Mehta, A., Block, T. M., Dwek, R. A. (1998). The role of N-glycosylation in the secretion of hepatitis B virus. *Adv. Exp. Med. Biol.* 435, 195-205.
- 30 30. Mehta, A., Rudd, P. M., Block, T. M., Dwek, R. A. (1997). A strategy for anti-viral intervention: the use of alpha-glycosidase inhibitors to

- prevent chaperone-mediated folding of viral envelope glycoproteins. *Biochem. Soc. Trans.* 25, 1188-1193.
31. Freeze, H. H., Westphal, V. C. (2001). Balancing N-linked glycosylation to avoid disease. *Biochimie* 83, 791-799.
- 5 32. Zitzmann, N., Mehta, A. S., Carrouee, S., Butters, T. D., Platt, F. M., McCauley, J., Blumberg, B. S., Dwek, R. A., Block, T. M. (1999). Imino sugars inhibit the formation and secretion of bovine diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents. *Proc. Natl. Acad. Sci. USA* 96, 10 11878-11882.
33. Mehta, A., Zitzmann, N., Rudd, P. M., Block, T. M., Dwek, R. A. (1998). Alpha-glucosidase inhibitors as potential broad-based anti-viral agents. *FEBS Lett.* 430, 17-22.
34. Rossen, J. W., de Beer, R., Godeke, G. J., Raamsman, M. J., 15 Horzinek, M.C., Vennema, H., and Rottier, P. J. (1998) The viral spike protein is not involved in the polarized sorting of coronaviruses in epithelial cells. *J Virol.* 72, 497-503.
35. Peiris, J. S. M., Lai, S. T., Poon, L. L. M., Guan, Y., Yam, L. Y. C., Lim, W., Nicholls, J., Yee, W. K. S., Yan, W. W., Cheung, M. T., Cheng, 20 V. C. C., Chan, K. H., Tsang, D. N. C., Yung, R. W. H., Ng, T. N., Yuen, K. Y., SARS study group (2003). Coronavirus as a possible cause of severe acute respiratory syndrome. *Lancet* 361, 1319-1325.
36. Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J. R., Hilgenfeld, R. (2003). Coronavirus Main Proteinase (3CL pro) Structure: Basis for 25 Design of Anti-SARS Drugs. *Science*, Published online 13 May, 10.1126/science.1085658.

Table 1 Calculated and measured masses for b and y ions from MS/MS measurements of the 2297.092 Da tryptic fragment.

y-ion	m/z found	m/z calc.	Δm (mDa)	Residue	Δm (mDa)	m/z found	m/z calc.	b-ion
y1	-	147.113	-	K	2	2279.083	2279.081	b20
y2	261.138	261.156	-18	N	-	-	2150.986	b19
y3	332.193	332.193		A			2036.943	b18
y4	389.197	389.215	-18	G	58		1965.906	b17
y5	552.283	552.278	5	Y	0	1908.885	1908.885	b16
y6	649.328	649.331	-3	P	-13	1745.809	1745.822	b15
y7	762.413	762.415	-2	L	21	1648.790	1648.769	b14
y8	849.438	849.447	-9	S	8	1535.694	1535.685	b13
y9	920.478	920.484	-6	A	-15	1448.638	1448.653	b12
y10	1049.522	1049.526	-4	E	19	1377.637	1377.616	b11
y11	1146.571	1146.579	-8	P	-	-	1248.573	b10
y12	1203.592	1203.601	-9	G	-4	1151.516	1151.520	b9
y13	1304.636	1304.648	-8	T	-5	1094.494	1094.499	b8
y14	1361.654	1361.670	-16	G	1	993.452	993.451	b7
y15	1474.739	1474.754	-15	L	-21	936.409	936.430	b6
y16	1637.818	1637.817	1	Y	11	823.357	823.346	b5
y17	1800.884	1800.881	3	Y	9	660.291	660.282	b4
y18	1947.970	1947.949	21	F	1	497.220	497.219	b3
y19	2111.022	2111.012	10	Y	-5	350.145	350.150	b2
y20	2297.086	2297.092	-6	W	-	-	187.087	b1

Table 2 Measured and calculated m/z values of peptides found in tryptic digest of the 46-kDa protein. M* represents oxidized methionine residues; Ac-SDN... is the acetylated N-terminal of the protein; Q** represents the N-terminal Gln residues converted into pyro-Glu; N*** represents an Asn residue converted into Asp due to deamidation.

m/z measured	MH ⁺ calculated (Da)	Δm (mDa)	Residues start-end	Peptide sequence
601.303	601.305	-3	204-209	GNSPAR
601.322	601.331	1	103-107	ELSPR
698.357	698.358	-1	144-149	DHIGTR
708.330	708.335	-5	96-102	GGDGKM*K
711.333	711.331	2	294-299	QGTDYK
746.387	746.383	4	356-361	HIDAYK
749.354	749.354	0	178-185	GGSQASSR
805.378	805.380	-2	196-203	NSTPGSSR
831.462	831.457	5	227-233	LNQLESK
876.452	876.461	-9	101-107	M*KELSPR
886.401	886.406	-5	170-177	GFYAEGSR
916.478	916.478	0	362-369	TFPPTPEK
928.543	928.546	-3	348-355	DNVILLNK
946.513	946.511	2	62-68	EELRFPR
1105.548	1105.553	-5	339-347	LDDKDPQFK
1144.493	1144.499	-6	1-10	Ac-SDNGPQSNQR
1154.579	1154.580	-1	376-387	TDEAQPLPQR
1166.557	1166.559	-2	267-276	Q**YNVTQAFGR
1183.589	1183.586	3	267-276	QYNVTQAFGR
1202.610	1202.613	-3	238-248	GQQQQGQTVTK
1282.678	1282.675	3	375-385	KTDEAQPLPQR
1330.698	1330.708	-10	238-249	GQQQQGQTVTKK
1410.774	1410.771	3	376-387	KKTDEAQPLPQR
1611.698	1611.692	6	406-421	QLQNSM*SGASADSTQA
1684.895	1684.891	4	128-293	EGIVWVATEGALNTPK
1687.898	1687.905	-7	210-226	MASGGGETALALLLLDR
1703.897	1703.900	-3	210-226	M*ASGGGETALALLLLDR

Table 2 (cont.)

1774.838	1774.836	2	278-293	GPEQTQGNFGDQDLIR
1850.833	1850.827	6	15-32	ITFGGPTDSTDNNQNGGR
1851.814	1850.811	3	15-32	ITFGGPTDSTDNNQN***GGR
1875.879	1875.879	0	389-405	Q**PTVTLLPAADM*DDFSR
1892.905	1892.906	-1	389-405	QPTVTLLPAADM*DDFSR
1930.944	1930.937	7	277-293	RGPEQTQGNFGDQDLIR
2005.008	2005.006	2	388-405	KQPTVTLLPAADMDDFSR
2015.081	2015.081	0	339-355	LDDKDPQFKDNVILLNK
2021.005	2021.001	4	388-405	KQPTVTLLPAADM*DDFSR
2077.048	2077.043	5	320-338	IGM*EVTPSGTWLTYHGAIK
2091.126	2091.120	-2	150-169	NPNNNAATVLQLPQGTTLPK
2151.002	2151.010	6	69-88	GQGVPIINTNSGPDDQIGYYR
2252.062	2252.071	-9	300-319	HWPQIAQFAPSASAFFGMSR
2297.078	2297.092	-14	108-127	WYFYLLGTGPEASLPYGANK
2307.128	2307.111	17	69-89	GQGVPIINTNSGPDDQIGYYRR
2324.187	2324.190	-3	41-61	RPQGLPNNTASWFTALTQHGK
2516.325	2516.339	-14	210-233	M*ASGGGETALALLLDRLNQLESK

Table 3 Deglycosylated peptides found in PNGase F-treated tryptic digest of 139-kDa spike protein. Bold N symbols represented deglycosylated sites.

Peptide	Sequence*	Calc. [M+H] ⁺ with no glycosylation	[M+H] ⁺ measured after PNGase	m/z diff.	No. sites	MS/MS deglyco. Peptide
T111-126	SQSVIIINNSTNVVIR	1756.992	1757.973	0.981	1	X
	SQSVIIINNSTNVVIR		1758.963	1.971	2	X
T222-232	LPLGINITNFR	1257.732	1258.715	0.983	1	X
T226-287	YDENGITDAV	2453.114	2454.101	0.987	1	X
	DCSQNPLAELK					
T316-333	FPNITNLCP GEVFNATK	2069.017	2071.001	1.984	2	X
T778-796	YFGGFNFSQ ILPDPLKPTK	2169.138	2170.121	0.983	1	X
T1056-1068	NFITAPAICHEGK	1445.685	1446.672	0.987	1	X
T1074-1089	EGVFVFNG TSWFITQR	1887.939	1888.931	0.922	1	X
T1140-1163	NHTSPDVDLGI	2493.259	2495.23	1.971	2	X
	SGINASVVNIQK					
T1174-1187	NLNESLIDLQELGK	1585.844	1586.823	0.979	1	X

Table 4 Glycosylated peptides found in tryptic digest of 139-kDa spike protein without treatment with PNGase F.

Peptide	Sequence	Calc. [M+H] ⁺ m/z	[M+H] ⁺ , meas. glyco- peptide	Residual Carbo. mass	Carbohydr . Compo- sition	Calc. carbo. mass	mass (meas. -calc.)	MS/MS glyco- peptide
T111-126	SQSVIIN	1756.992	3201.514	1444.522	M3N4F	1444.534	-0.012	
	NSTNVV		3404.572	1647.580	M3N5F	1647.613	-0.033	X
	IR		3525.669	1768.677	M3N4G2F	1768.640	0.037	
			3566.670	1809.678	M3N5GF	1809.666	0.012	
			3607.682	1850.690	M3N6F	1850.693	-0.003	X
			3728.687	1971.695	M3N5G2F	1971.719	-0.024	
			3769.678	2012.686	M3N6GF	2012.745	-0.059	
			3890.761	2133.769	M3N5G3F	2133.772	-0.003	
			3931.793	2174.801	M3N6G2F	2174.798	0.030	
			4093.818	2336.826	M3N6G3F	2336.859	-0.025	X
			4255.844	2498.852	M3N6G4F	2498.904	0.052	
			4296.905	2539.913	M3N7G3F	2539.930	-0.017	
T222-232	LPLGINI	1257.732	2636.215	1378.483	M6N2	1378.746	0.007	
	TNFR		2798.26	1540.528	M7N2	1540.528	0.000	
			2960.306	1702.574	M8N2	1702.574	-0.007	
			3122.373	1864.641	M9N2	1864.641	0.007	X
T226-287	YDENG	2453.114	4100.666	1647.552	M3N5F	1647.613	-0.061	
	ITDAVD		4303.735	1850.621	M3N6F	1850.693	0.072	X
	CSQNPL		4427.1*	1974.0	M3N5FG2	1971.719		
	AELK		4468.9*	2015.8	M3N6FG	2012.745		
			4589.1*	2136.0	M3N5G3F	2133.772		
			4792.2*	2399.1	M3N6G3F	2336.859		
			4953.9*	2500.8	M3N6G4F	2498.904		

Table 4 (cont.)

T778-796	YFGGFN	2169.138	3385.59	1216.452	M5N2	1216.423	-0.029	
	FSQILPD		3547.644	1378.506	M6N2	1378.476	-0.030	
	PLKPTK		3709.738	1540.600	M7N2	1540.529	-0.071	X
			3871.702	1702.564	M8N2	1702.581	0.017	

Peptide Symbols

N: first glycosylation site

N: second glycoylation site

Carbohydrate composition symbols:

M = mannose

F = fucose

G = galactose

N = N-acetyl glucosamine

*m/z values could not be determined accurately (see text)

Table 5 Measured and calculated m/z values of peptides found in tryptic digests of the 139-kDa protein. Mass values are taken directly from the automatic peak finding program, and are therefore somewhat less reliable than when they are checked manually. A) without deglycosylation of the 39 peptides observed (34% coverage). 36 were confirmed by MS/MS (30% coverage). B) After deglycosylation with PNGaseF (see text) nine deglycosylated peptides were found and confirmed by MS/MS giving an additional 12% coverage. M* - oxidized Met residues; ** - peptide identifications not confirmed by MS/MS; D – deglycosylated Asn residues.

m/z measured	MH- Calculated (Da)	Δm (mDa)	Residues start-end	Peptide sequence
A				
653.344	653.341	3	1069-1073	AYFPR
669.361	669.361	0	184-188	EFVFK
673.389	673.388	1	1168-1173	LNEVAK**
725.332	725.329	3	1022-1027	VDFCGK
738.370	738.367	3	292-297	SFEIDK
817.478	817.468	10	448-453	LRPFER
820.470	820.457	13	762-768	EVFAQVK
846.476	846.468	8	1002-1010	ASANLAATK
847.453	847.434	19	830-836	DLICAQK
881.446	881.430	16	1021-1027	RVDFCGK
885.420	885.414	6	366-373	CYGVSATK
927.543	927.526	17	307-315	VVPSGDVVR
962.523	962.506	17	904-911	QIANQFNK
1046.556	1046.563	-7	199-207	GYQPIDVVR
1068.533	1068.540	-7	808-817	VTLDAGFM*K**
1085.553	1085.538	15	298-306	GIYQTSNFR
1114.534	1114.542	-8	85-94	DGIYFAATEK
1130.592	1130.581	11	748-758	ALSQIAAEQDR
1154.555	1154.563	-8	334-342	FPSVYAWER
1154.564	1154.574	-10	545-553	FOFPQQFGR
1225.641	1225.647	-6	798-807	SFIEDLLFNK
1246.646	1246.647	-1	189-198	NKDGFLYVYK
1258.602	1258.610	-8	39-48	GVYFDEIFR

Table 5 (cont.)

1310.663	1310.675	-12	544-553	RFOPFQQFQR
1395.622	1395.632	-10	818-829	QYGECLGDINAR
1414.754	1414.754	0	966-977	LDKVEAEVQIDR
1460.690	1460.666	24	427-439	NIDATSTGNYNYK
1480.687	1480.692	-5	554-566	DVSDFTDSVRDPK
1575.866	1576.874	-8	208-221	DLPSQFNTLKPIFK
1690.951	1690.949	2	983-996	LQSLQTYVTQQLIR
1737.879	1737.881	-2	396-411	QIAPGQTGVIADYNYK
1804.885	1804.887	-2	292-306	SFEIDKGIYQTSNFR
1810.834	1810.825	-1	412-436	LPDDFM*QCVLAWNTR
1848.979	1848.992	-13	912-929	AISQIQESLTTTSTALGK
1868.012	1868.024	-12	930-946	LQDVVNQNAQALNTLVK
1990.954	1990.958	-4	374-390	LNDLCFSNVYADSFVVK
2014.091	2014.104	-13	496-514	VVVSFELLNAPATVCGPK
2355.139	2355.140	-1	522-543	NQCVNFNFNGLTGTGVLTPSSK
3183.578	3183.584	-6	1028-1055	GYHLM*SFPQAAPHGVVFLHVTYVPSOER**

B Deglycosylated peptides found in PNGase-treated tryptic digest

1258.715	1258.716	-1	222-232	LPLGIDITNFR
1446.672	1446.669	3	1056-1068	DFTTAPAICHEGK
1586.803	1586.808	-5	1174-1187	NLDESLIDLQELGK
1757.973	1757.976	-3	111-126	SQSVIIINDSTNVVIR
1758.963	1758.960	3	111-126	SQSVIIIDDSTNVVIR
1888.931	1888.923	8	1074-1089	EGVFVFDGTSWFITQR
2071.001	2070.985	16	316-333	FPDITNLCPFGEVFDATK
2170.121	2170.122	-1	778-796	YEGGFDFSOILPDPLKPTK
2454.101	2454.098	3	226-287	YDEDGTITDAVDCSONFLAELK
2495.230	3495.227	3	1140-1163	DHTSPDVDLGDISGIDASVVNIQK

WE CLAIM:

1. An isolated SARS-related protein having a molecular weight of approximately 47 kDa.
- 5 2. The protein of claim 1, having a sequence as shown in Figure 1 and homologs, analogs, fragments or derivatives thereof.
3. An isolated SARS-related protein having a molecular weight of approximately 139 kDa.
4. The protein of claim 3, having a sequence as shown in Figure 2
10 and homologs, analogs, fragments or derivatives thereof.
5. An antibody reactive against a protein according to any one of claims 1 to 4.
6. A method of detecting a coronavirus or a condition associated with a coronavirus comprising assaying a sample for (a) a SARS-related
15 protein or a fragment thereof; or (b) an antibody that binds a SARS-related protein or a fragment thereof.
7. A method according to claim 6 which comprises contacting a SARS-related protein of any one of claims 1 to 4 or a functional fragment thereof, with the sample and determining the presence of antibodies to the
20 SARS-related protein in the sample.
8. A method according to claim 6 which comprises contacting an antibody of claim 5, or a functional fragment thereof, with the sample and determining the presence of a SARS-related protein in the sample.
9. A method according to any one of claims 6 to 8 wherein the
25 condition is SARS.
10. A method of treating or preventing a condition associated with coronavirus comprising administering an effective amount of a SARS-related protein antagonist.
11. A method according to claim 10 wherein said SARS-related
30 protein antagonist is an antibody according to claim 5.
12. A method according to claim 10 or 11 wherein said condition is SARS.

13. A vaccine for treating or preventing a condition associated with a coronavirus comprising an effective amount of (a) a SARS-related protein or fragment thereof; or (b) an antibody that binds a SARS-related protein in admixture with a suitable diluent or carrier.
- 5 14. A method of screening for a compound capable of binding to a protein according to any one of claims 1 to 4, or a functional fragment thereof comprising contacting the polypeptide or functional fragment thereof with a test compound and determining the ability of said test compound to bind to said protein or fragment thereof.
- 10 15. A compound identified according the method of claim 14.
16. The compound of claim 14 wherein said compound is an agonist or antagonist.

FIGURE 1

47 kDa protein sequence, noon Apr 15, 2003

MW 45936.94 average, 421 aa, 93 % sequence coverage (confirmed residues indicated in red). @S indicates acetylation of the N-terminal serine residue (yielding a mass change +42.011 Da)

1/12

1 @SDNGPQSNQR SAPRITFGGP TDSTDNNQNG GRNGARPKQR RPQGLPNNNTA SWFTALTQHG
 61 KEELRFPRGQ GVPINTNSGP DDQIGYYRRA TRRVRGGDGK **M**KELSPRWYF YYLGTGPEAS
 121 LPYGANKEGI VVVALEGALN TPKDHIGTRN PNNNAATVLQ LPQGTTLPKG FYAEGSRGGS
 181 QASSRSSRS RGNSRNSTPG SSRGNSPAR**M** ASGGGETALA LLLDLRLNQL ESKVSGKGQQ
 241 QQGQTVTKKS AAEASKKPRQ KRTATKQYNV TQAFGRRGPE QTQGNFGDQD LIRQGTDYKH
 301 WPQIAQFAPS ASAFFG**MS**RI GMEVTPSGTW LTYHGAIKLD DKDPQFKDNV ILLNKHIDAY
 361 KTFPPTEPKK DKKKKTD~~EAQ~~ PLPQRQKKQ**P** TVTLLPAAD**M** DDFSRLQ**L**NS **M**SGASADSTQ
 421 A

FIGURE 2

SARS protein 139 kDa

```

FIFLLFL TLTSGLDLDR CTTFDDVQAP NYTQHTSSMR GVYYPDEIFR SDTLYLTQDL
FLPFYSNVTG FHTINHTEFGN PVIPFKDGIY FAATEKSNVV RGWVFGSTMN NKSQSIIIN
NSTNVVIRAC NFELCDNPFF AVSKPMGTQT HTMIFDNAFN CTFEYISDAF SLDVSEKSGN
FKHLREFVFK NKDGFLYVYK GYQPIDVVRD LPSGFNTLKP IFKLPLGINI TNFRAILTAF
SPAQDIWGTS AAAYFVGYLK PTTFMLKYDE NGTITDAVDC SQNPLAELKC SVKSFEIDKG
IYQTSNFRVV PSGDVVRFPN ITNLCPFGEV FNATKFPSVY AWERKKISNC VADYSVLNS
TFFSTFKCYG VSATKLNDLC FSNVYADSFV VKGDDVRQIA PGQTGVIADY NYKLPDDFMG
CVLAWNTRNI DATSTGNYNY KYRYLRHGKL RPFERDISNV PFSPDGKPCT PPALNCYWPL
NDYGFYTTTG IGYQPYRVVV LSFELLNAPA TVCGPKLSTD LIKNCVNFN FNGLTGTGVL
TPSSKRFPF QFGRDVSDF TDSVRDPKTS EILDISPCAF GGVSVITPGT NASSEVAVLY
QDVNCTDVST AIHADQLTPA WRIYSTGNNV FQTQAGCLIG AEHVDTSYEC DIPIGAGICA
SYHTVSLIRS TSQKSIVAYT MSLGADSSIA YSNTTIAIPT NFSISITTEV MPVSMAKTSV
DCNMYICGDS TECANLLLQY GSFCTQLNRA LSGIAAEQDR NTREVFAQVK QMYKTPTLKY
FGGFNFSQIL PDPLKPTKRS FIEDLLFNKV TLADAGFMKQ YGEC LGDINA RDLICAQKFN
GLTVLPPLLT DDMIAAYTAA LVSGTATAGW TFGAGAALQI PFAMQMAYRF NGIGVTQNVL
YENQKQIANQ FNKAISQIQE SLTTTSTALG KLQDVVNQNA QALNTLVKQL SSNFGAIISSV
LNDILSRDLK VEAQVQIDRL ITGRLQSLQT YVTQQLIRAA EIRASANLAA TKMSECVLGQ
SKRVDFCGKG YHLMSPQAA PHGVVFLHVT YVPSQERNFT TAPAICHEGK AYFPREGVVF
FNGTSWFITQ RNFFSPQIIT TDNTFVSGNC DVVIGIINNT VYDPLQPELD SFKEELDKYF
KNHTSPDVDL GDISGINASV VNIQKEIDRL NEVAKNLNES LIDLQELGKY EQYIKWPWYV
WLGFIAGLIA IVMVTILLECC MTSCCSCLKG ACSCGSCCKF DEDDSEPVLK GVKLHYT

```




FIGURE 3




FIGURE 4




FIGURE 5

Coronavirus Nucleocapsid Protein Homology

...	WYFYLLGTGPEASLPYCAN	...	SARS
...	WYFYLLGTGPHAKDQYGTD	...	Human
...	WYFYLLGTGPHAKDQYGTD	...	Bovine
...	WYFYLLGTGPHAKDQYGTD	...	Turkey
...	WYFYLLGTGPHAKHQYGTD	...	Porcine
...	WYFYLLGTGPHAKAQYGTN	...	Equine
...	WYFYLLGTGPHAGASYGDD	...	Murine
...	WYFYLLGTGPHAGASFGDS	...	Rat

FIGURE 6




FIGURE 7




FIGURE 8




FIGURE 9




FIGURE 10

A

1 SDNGPQSNQR SAPRITFGGP TDSTDNNQNG GRNGARPKQR RPQGLPNNTA SWFTALTQHG
 61 KEELRFFPRGQ GVPINTNSGP DDQIGYYRRA TRVRVGGDGK MKELSPRWYF YYLGTGPEAS
 121 LPYGANKEGI VVATEGALN TPKDHIGTRN PNNNAATVLQ LPQGTTLPGK FYAEGSRGGS
 181 QASSRRSSRS RGNSRNSSTPG SSGNSPARM ASGGGETALA LLLDLRLNQL ESKVSGKGQQ
 241 QQGQTVTKKS AAEASKKPRQ KRTATKQYNV TQAFGRRGPE QTQGNFGDQD LIRQGTDYKH
 301 WPQIAQFAPS ASAFFGMSRI GMEVTPSGTW LTYHGAIKLD DKDPQFKDNV ILLNKHIDAY
 361 KTFPPTEPKK DKKKKTDEAQ PLPQRQKKQP TVTLLPAADM DDFSRLQNS MSGASADSTQ
 421 A

B




FIGURE 11




FIGURE 12

Untitled.ST25
SEQUENCE LISTING

<110> University of Manitoba
Her Majesty the Queen in Right of Canada as Represented by
the Minister of Health

<120> SARS-RELATED PROTEINS

<130> 85084-1003

<150> US 60/462688

<151> 2003-04-15

<150> US 60/472416

<151> 2003-05-22

<160> 2

<170> PatentIn version 3.2

<210> 1

<211> 421

<212> PRT

<213> coronavirus

<400> 1

Ser Asp Asn Gly Pro Gln Ser Asn Gln Arg Ser Ala Pro Arg Ile Thr
1 5 10 15

Phe Gly Gly Pro Thr Asp Ser Thr Asp Asn Asn Gln Asp Gly Gly Arg
20 25 30

Asn Gly Ala Arg Pro Lys Gln Arg Arg Pro Gln Gly Leu Pro Asn Asn
35 40 45

Thr Ala Ser Trp Phe Thr Ala Leu Thr Gln His Gly Lys Glu Glu Leu
50 55 60

Arg Phe Pro Arg Gly Gln Gly Val Pro Ile Asn Thr Asn Ser Gly Pro
65 70 75 80

Asp Asp Gln Ile Gly Tyr Tyr Arg Arg Ala Thr Arg Arg Val Arg Gly
85 90 95

Gly Asp Gly Lys Met Lys Glu Leu Ser Pro Arg Trp Tyr Phe Tyr Tyr
100 105 110

Leu Gly Thr Gly Pro Glu Ala Ser Leu Pro Tyr Gly Ala Asn Lys Glu
115 120 125

Gly Ile Val Trp Val Ala Thr Glu Gly Ala Leu Asn Thr Pro Lys Asp
130 135 140

Untitled.ST25

His Ile Gly Thr Arg Asn Pro Asn Asn Asn Ala Ala Thr Val Leu Gln
 145 150 155 160
 Leu Pro Gln Gly Thr Thr Leu Pro Lys Gly Phe Tyr Ala Glu Gly Ser
 165 170 175
 Arg Gly Gly Ser Gln Ala Ser Ser Arg Ser Ser Ser Arg Ser Arg Gly
 180 185 190
 Asn Ser Arg Asn Ser Thr Pro Gly Ser Ser Arg Gly Asn Ser Pro Ala
 195 200 205
 Arg Met Ala Ser Gly Gly Gly Glu Thr Ala Leu Ala Leu Leu Leu Leu
 210 215 220
 Asp Arg Leu Asn Gln Leu Glu Ser Lys Val Ser Gly Lys Gly Gln Gln
 225 230 235 240
 Gln Gln Gly Gln Thr Val Thr Lys Lys Ser Ala Ala Glu Ala Ser Lys
 245 250 255
 Lys Pro Arg Gln Lys Arg Thr Ala Thr Lys Gln Tyr Asn Val Thr Gln
 260 265 270
 Ala Phe Gly Arg Arg Gly Pro Glu Gln Thr Gln Gly Asn Phe Gly Asp
 275 280 285
 Gln Asp Leu Ile Arg Gln Gly Thr Asp Tyr Lys His Trp Pro Gln Ile
 290 295 300
 Ala Gln Phe Ala Pro Ser Ala Ser Ala Phe Phe Gly Met Ser Arg Ile
 305 310 315 320
 Gly Met Glu Val Thr Pro Ser Gly Thr Trp Leu Thr Tyr His Gly Ala
 325 330 335
 Ile Lys Leu Asp Asp Lys Asp Pro Gln Phe Lys Asp Asn Val Ile Leu
 340 345 350
 Leu Asn Lys His Ile Asp Ala Tyr Lys Thr Phe Pro Pro Thr Glu Pro
 355 360 365
 Lys Lys Asp Lys Lys Lys Lys Thr Asp Glu Ala Gln Pro Leu Pro Gln
 370 375 380
 Arg Gln Lys Lys Gln Pro Thr Val Thr Leu Leu Pro Ala Ala Asp Met
 385 390 395 400

Untitled.ST25

Asp Asp Phe Ser Arg Gln Leu Gln Asn Ser Met Ser Gly Ala Ser Ala
 405 410 415

Asp Ser Thr Gln Ala
 420

<210> 2
 <211> 1254
 <212> PRT
 <213> coronavirus

<300>
 <301> Krokhin et al.
 <302> Mass Spectrometric Characterization of Proteins from the SARS
 virus: A Preliminary Report
 <303> Mol. Cell. Proteomics
 <304> 2
 <305> 5
 <306> 346-356
 <307> 2003-05-29

<400> 2

Phe Ile Phe Leu Leu Phe Leu Thr Leu Thr Ser Gly Ser Asp Leu Asp
 1 5 10 15

Arg Cys Thr Thr Phe Asp Asp Val Gln Ala Pro Asn Tyr Thr Gln His
 20 25 30

Thr Ser Ser Met Arg Gly Val Tyr Tyr Pro Asp Glu Ile Phe Arg Ser
 35 40 45

Asp Thr Leu Tyr Leu Thr Gln Asp Leu Phe Leu Pro Phe Tyr Ser Asn
 50 55 60

Val Thr Gly Phe His Thr Ile Asn His Thr Phe Gly Asn Pro Val Ile
 65 70 75 80

Pro Phe Lys Asp Gly Ile Tyr Phe Ala Ala Thr Glu Lys Ser Asn Val
 85 90 95

Val Arg Gly Trp Val Phe Gly Ser Thr Met Asn Asn Lys Ser Gln Ser
 100 105 110

Val Ile Ile Ile Asn Asn Ser Thr Asn Val Val Ile Arg Ala Cys Asn
 115 120 125

Phe Glu Leu Cys Asp Asn Pro Phe Phe Ala Val Ser Lys Pro Met Gly
 130 135 140

Thr Gln Thr His Thr Met Ile Phe Asp Asn Ala Phe Asn Cys Thr Phe

Untitled.ST25

145 150 155 160
 Glu Tyr Ile Ser Asp Ala Phe Ser Leu Asp Val Ser Glu Lys Ser Gly
 165 170 175
 Asn Phe Lys His Leu Arg Glu Phe Val Phe Lys Asn Lys Asp Gly Phe
 180 185 190
 Leu Tyr Val Tyr Lys Gly Tyr Gln Pro Ile Asp Val Val Arg Asp Leu
 195 200 205
 Pro Ser Gly Phe Asn Thr Leu Lys Pro Ile Phe Lys Leu Pro Leu Gly
 210 215 220
 Ile Asn Ile Thr Asn Phe Arg Ala Ile Leu Thr Ala Phe Ser Pro Ala
 225 230 235 240
 Gln Asp Ile Trp Gly Thr Ser Ala Ala Ala Tyr Phe Val Gly Tyr Leu
 245 250 255
 Lys Pro Thr Thr Phe Met Leu Lys Tyr Asp Glu Asn Gly Thr Ile Thr
 260 265 270
 Asp Ala Val Asp Cys Ser Gln Asn Pro Leu Ala Glu Leu Lys Cys Ser
 275 280 285
 Val Lys Ser Phe Glu Ile Asp Lys Gly Ile Tyr Gln Thr Ser Asn Phe
 290 295 300
 Arg Val Val Pro Ser Gly Asp Val Val Arg Phe Pro Asn Ile Thr Asn
 305 310 315 320
 Leu Cys Pro Phe Gly Glu Val Phe Asn Ala Thr Lys Phe Pro Ser Val
 325 330 335
 Tyr Ala Trp Glu Arg Lys Lys Ile Ser Asn Cys Val Ala Asp Tyr Ser
 340 345 350
 Val Leu Tyr Asn Ser Thr Phe Phe Ser Thr Phe Lys Cys Tyr Gly Val
 355 360 365
 Ser Ala Thr Lys Leu Asn Asp Leu Cys Phe Ser Asn Val Tyr Ala Asp
 370 375 380
 Ser Phe Val Val Lys Gly Asp Asp Val Arg Gln Ile Ala Pro Gly Gln
 385 390 395 400

Untitled.ST25

Thr Gly Val Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe Met
 405 410 415
 Gly Cys Val Leu Ala Trp Asn Thr Arg Asn Ile Asp Ala Thr Ser Thr
 420 425 430
 Gly Asn Tyr Asn Tyr Lys Tyr Arg Tyr Leu Arg His Gly Lys Leu Arg
 435 440 445
 Pro Phe Glu Arg Asp Ile Ser Asn Val Pro Phe Ser Pro Asp Gly Lys
 450 455 460
 Pro Cys Thr Pro Pro Ala Leu Asn Cys Tyr Trp Pro Leu Asn Asp Tyr
 465 470 475 480
 Gly Phe Tyr Thr Thr Thr Gly Ile Gly Tyr Gln Pro Tyr Arg Val Val
 485 490 495
 Val Leu Ser Phe Glu Leu Leu Asn Ala Pro Ala Thr Val Cys Gly Pro
 500 505 510
 Lys Leu Ser Thr Asp Leu Ile Lys Asn Gln Cys Val Asn Phe Asn Phe
 515 520 525
 Asn Gly Leu Thr Gly Thr Gly Val Leu Thr Pro Ser Ser Lys Arg Phe
 530 535 540
 Gln Pro Phe Gln Gln Phe Gly Arg Asp Val Ser Asp Phe Thr Asp Ser
 545 550 555 560
 Val Arg Asp Pro Lys Thr Ser Glu Ile Leu Asp Ile Ser Pro Cys Ala
 565 570 575
 Phe Gly Gly Val Ser Val Ile Thr Pro Gly Thr Asn Ala Ser Ser Glu
 580 585 590
 Val Ala Val Leu Tyr Gln Asp Val Asn Cys Thr Asp Val Ser Thr Ala
 595 600 605
 Ile His Ala Asp Gln Leu Thr Pro Ala Trp Arg Ile Tyr Ser Thr Gly
 610 615 620
 Asn Asn Val Phe Gln Thr Gln Ala Gly Cys Leu Ile Gly Ala Glu His
 625 630 635 640
 Val Asp Thr Ser Tyr Glu Cys Asp Ile Pro Ile Gly Ala Gly Ile Cys
 645 650 655

Untitled.ST25

Ala Ser Tyr His Thr Val Ser Leu Leu Arg Ser Thr Ser Gln Lys Ser
 660 665 670
 Ile Val Ala Tyr Thr Met Ser Leu Gly Ala Asp Ser Ser Ile Ala Tyr
 675 680 685
 Ser Asn Asn Thr Ile Ala Ile Pro Thr Asn Phe Ser Ile Ser Ile Thr
 690 695 700
 Thr Glu Val Met Pro Val Ser Met Ala Lys Thr Ser Val Asp Cys Asn
 705 710 715 720
 Met Tyr Ile Cys Gly Asp Ser Thr Glu Cys Ala Asn Leu Leu Leu Gln
 725 730 735
 Tyr Gly Ser Phe Cys Thr Gln Leu Asn Arg Ala Leu Ser Gly Ile Ala
 740 745 750
 Ala Glu Gln Asp Arg Asn Thr Arg Glu Val Phe Ala Gln Val Lys Gln
 755 760 765
 Met Tyr Lys Thr Pro Thr Leu Lys Tyr Phe Gly Gly Phe Asn Phe Ser
 770 775 780
 Gln Ile Leu Pro Asp Pro Leu Lys Pro Thr Lys Arg Ser Phe Ile Glu
 785 790 795 800
 Asp Leu Leu Phe Asn Lys Val Thr Leu Ala Asp Ala Gly Phe Met Lys
 805 810 815
 Gln Tyr Gly Glu Cys Leu Gly Asp Ile Asn Ala Arg Asp Leu Ile Cys
 820 825 830
 Ala Gln Lys Phe Asn Gly Leu Thr Val Leu Pro Pro Leu Leu Thr Asp
 835 840 845
 Asp Met Ile Ala Ala Tyr Thr Ala Ala Leu Val Ser Gly Thr Ala Thr
 850 855 860
 Ala Gly Trp Thr Phe Gly Ala Gly Ala Ala Leu Gln Ile Pro Phe Ala
 865 870 875 880
 Met Gln Met Ala Tyr Arg Phe Asn Gly Ile Gly Val Thr Gln Asn Val
 885 890 895
 Leu Tyr Glu Asn Gln Lys Gln Ile Ala Asn Gln Phe Asn Lys Ala Ile
 900 905 910

Untitled.ST25

Ser Gln Ile Gln Glu Ser Leu Thr Thr Thr Ser Thr Ala Leu Gly Lys
 915 920 925

Leu Gln Asp Val Val Asn Gln Asn Ala Gln Ala Leu Asn Thr Leu Val
 930 935 940

Lys Gln Leu Ser Ser Asn Phe Gly Ala Ile Ser Ser Val Leu Asn Asp
 945 950 955 960

Ile Leu Ser Arg Leu Asp Lys Val Glu Ala Glu Val Gln Ile Asp Arg
 965 970 975

Leu Ile Thr Gly Arg Leu Gln Ser Leu Gln Thr Tyr Val Thr Gln Gln
 980 985 990

Leu Ile Arg Ala Ala Glu Ile Arg Ala Ser Ala Asn Leu Ala Ala Thr
 995 1000 1005

Lys Met Ser Glu Cys Val Leu Gly Gln Ser Lys Arg Val Asp Phe
 1010 1015 1020

Cys Gly Lys Gly Tyr His Leu Met Ser Phe Pro Gln Ala Ala Pro
 1025 1030 1035

His Gly Val Val Phe Leu His Val Thr Tyr Val Pro Ser Gln Glu
 1040 1045 1050

Arg Asn Phe Thr Thr Ala Pro Ala Ile Cys His Glu Gly Lys Ala
 1055 1060 1065

Tyr Phe Pro Arg Glu Gly Val Phe Val Phe Asn Gly Thr Ser Trp
 1070 1075 1080

Phe Ile Thr Gln Arg Asn Phe Phe Ser Pro Gln Ile Ile Thr Thr
 1085 1090 1095

Asp Asn Thr Phe Val Ser Gly Asn Cys Asp Val Val Ile Gly Ile
 1100 1105 1110

Ile Asn Asn Thr Val Tyr Asp Pro Leu Gln Pro Glu Leu Asp Ser
 1115 1120 1125

Phe Lys Glu Glu Leu Asp Lys Tyr Phe Lys Asn His Thr Ser Pro
 1130 1135 1140

Asp Val Asp Leu Gly Asp Ile Ser Gly Ile Asn Ala Ser Val Val

Untitled.ST25

1145

1150

1155

Asn Ile Gln Lys Glu Ile Asp Arg Leu Asn Glu Val Ala Lys Asn
1160 1165 1170

Leu Asn Glu Ser Leu Ile Asp Leu Gln Glu Leu Gly Lys Tyr Glu
1175 1180 1185

Gln Tyr Ile Lys Trp Pro Trp Tyr Val Trp Leu Gly Phe Ile Ala
1190 1195 1200

Gly Leu Ile Ala Ile Val Met Val Thr Ile Leu Leu Cys Cys Met
1205 1210 1215

Thr Ser Cys Cys Ser Cys Leu Lys Gly Ala Cys Ser Cys Gly Ser
1220 1225 1230

Cys Cys Lys Phe Asp Glu Asp Asp Ser Glu Pro Val Leu Lys Gly
1235 1240 1245

Val Lys Leu His Tyr Thr
1250